University of Pennsylvania

ScholarlyCommons
Publicly Accessible Penn Dissertations

2019

Trpv5: Structure, Function And Drug Discovery
Taylor Hughes
University of Pennsylvania, tehughes15@gmail.com

Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Biochemistry Commons, Molecular Biology Commons, and the Pharmacology
Commons
Recommended Citation
Hughes, Taylor, "Trpv5: Structure, Function And Drug Discovery" (2019). Publicly Accessible Penn Dissertations. 3385.
https://repository.upenn.edu/edissertations/3385

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/3385
For more information, please contact repository@pobox.upenn.edu.

Trpv5: Structure, Function And Drug Discovery
Abstract

The transient receptor potential vanilloid 5 (TRPV5) channel is a highly calcium selective ion channel that
regulates systemic calcium homeostasis by acting as a critical gate for calcium reabsorption in the kidney.
Human polymorphisms of this channel have exemplified the importance of TRPV5 in disorders of calcium
homeostasis, but atomic level information regarding this channel had remained unknown. To address this gap,
we utilized cryo-electron microscopy (cryo-EM) coupled with computational and biochemical approaches to
understand the gating and modulation of TRPV5. First, we investigated the mechanism of action of the
inhibitor econazole on TRPV5 which yielded the first reported structure of this protein. From that structure
we were able to identify the econazole binding site and gain insights into how binding of a modulator in that
pocket would result in channel inhibition. We then sought to elucidate the mechanism of action of
endogenous modulators of TRPV5 including the intracellular calcium binding protein calmodulin (CaM) and
the abundant plasma membrane phospholipid phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) which act
as an inhibitor and activator, respectively. By solving the structures of TRPV5 in the presence of these
modulators as well as TRPV5 in an apo state we clearly identified the binding regions for these two
modulators and the conformational changes that confer inhibition or activation. Finally, using the structural
information that we had gathered coupled with structure-based virtual screening we uncovered two novel
inhibitors of TRPV5 both of which bound in different sites on the protein and revealed novel mechanisms of
inhibition of TRPV5. These studies have thus expanded the base of understanding of TRPV5 at the atomic
level and laid the foundation for future studies including but not limited to rational drug design, molecular
dynamics investigations and targeted biochemical probing.
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ABSTRACT
TRPV5: STRUCTURE, FUNCTION AND DRUG DISCOVERY
Taylor Elizabeth Tiare Hughes
Vera Moiseenkova-Bell, PhD
The transient receptor potential vanilloid 5 (TRPV5) channel is a highly calcium selective
ion channel that regulates systemic calcium homeostasis by acting as a critical gate for calcium
reabsorption in the kidney. Human polymorphisms of this channel have exemplified the
importance of TRPV5 in disorders of calcium homeostasis, but atomic level information regarding
this channel had remained unknown. To address this gap, we utilized cryo-electron microscopy
(cryo-EM) coupled with computational and biochemical approaches to understand the gating and
modulation of TRPV5. First, we investigated the mechanism of action of the inhibitor econazole
on TRPV5 which yielded the first reported structure of this protein. From that structure we were
able to identify the econazole binding site and gain insights into how binding of a modulator in
that pocket would result in channel inhibition. We then sought to elucidate the mechanism of
action of endogenous modulators of TRPV5 including the intracellular calcium binding protein
calmodulin (CaM) and the abundant plasma membrane phospholipid phosphatidylinositol 4,5bisphosphate (PI(4,5)P2) which act as an inhibitor and activator, respectively. By solving the
structures of TRPV5 in the presence of these modulators as well as TRPV5 in an apo state we
clearly identified the binding regions for these two modulators and the conformational changes
that confer inhibition or activation. Finally, using the structural information that we had gathered
coupled with structure-based virtual screening we uncovered two novel inhibitors of TRPV5 both
of which bound in different sites on the protein and revealed novel mechanisms of inhibition of
TRPV5. These studies have thus expanded the base of understanding of TRPV5 at the atomic
level and laid the foundation for future studies including but not limited to rational drug design,
molecular dynamics investigations and targeted biochemical probing.
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CHAPTER 1: INTRODUCTION
1.1 Calcium Homeostasis and Associated Diseases
Calcium is an essential ion in the body that is involved in a variety of cellular
processes from cell contractility to bone growth and stability1. The three major systems
involved in overall calcium homeostatic balance are the bone, the intestines and the
kidneys1. Calcium homeostasis in these systems is regulated by the calcitropic
hormones

parathyroid

hormone

(PTH)

and

1,25-dihydroxycholecalciferol

(1,25-

(OH)2D3)2. In the bone, calcium is both absorbed and excreted in equal quantities such
that in a healthy individual there is minimal net gain or loss of calcium1. The bone is thus
susceptible to acute and chronic changes in overall calcium homeostasis. The intestines
and kidney absorb and excrete calcium respectively such that the net balance of the
system meets the needs of the cells and tissues that utilize the calcium for their
function1.
Disruption of calcium homeostasis can be caused by diseases such as cancer or
diabetes and can lead to a host of calcium-related disorders. Additionally, a decline in
calcium

homeostatic

balance

is

associated

with

aging3.

Hypercalciuria

and

hypercalcemia are common disorders of calcium metabolism and are diagnosed based
on the ionic calcium present in the urine or serum4.
Hypercalciuria is defined as an excess of ionic calcium found in the urine. While
sometimes seen with hypocalcemia, some types of hypercalciuria occur in spite of
normal levels of calcium in the blood4. Hypercalciuria, also known as calcium wasting,
can be heritable or caused by metabolic diseases such as diabetes, though the vast
majority of cases are idiopathic5. Hypercalciuria is typically asymptomatic in nature, but
is known to be a critical risk factor for the development of nephrolithiasis5. Commonly
1

known as kidney stone disease, nephrolithiasis affects up to 5% of American women
and 12% of men in their lifetime. As such, nephrolithiasis results in a significant financial
burden to society with the total cost of hospitalization and treatment estimated to exceed
$1 billion per year in the United States6,7. Kidney stones are caused by the
supersaturation of salts in the lumen of the kidney nephron7. The vast majority (~80%) of
kidney stones are calcium-based, and therefore, systemic calcium homeostasis plays a
major role in stone formation7. While the creation and passing of small kidney stones
can be asymptomatic, larger stones can cause hematuria, intense renal colic and
potentially cause long-term damage to the kidney7. Another aspect of nephrolithiasis is
the high recurrence rate of stones. For adults, within seven years of the first stone there
is a 50% chance of the formation of a second stone, and for children the recurrence rate
has been reported to be as high as 50% within 3 years8,9.
Hypercalcemia is defined as high levels of ionic calcium present in the serum.
Depending on the severity, symptoms can range from common gastrointestinal distress
such as nausea and vomiting to cardiovascular problems including a short QT interval
and hypertension4. Hypercalcemia also has the serious potential to cause acute renal
failure. Typical causes of hypercalcemia include cancer malignancy in the bone,
hyperparathyroidism and genetic disorders like familial hypocalciuric hypercalcemia4.
This condition can also be the result of overabundant PTH production after a kidney
transplant4. Specifically, in the case of kidney transplants, persistent hypercalcemia is
correlated

with

nephrocalcinosis

and

a

higher

risk

of

transplant

loss10,11.

Nephrocalcinosis is defined as the increase of calcium content in the kidney, typically in
the tubular and interstitial compartments10,12. Similar to nephrolithiasis, tubulointerstitial
calcification causes a build up of calcium oxalate or calcium phosphate in both the
2

tubular and interstitial compartments of the medulla. These calcium deposits tend to not
pass through the kidney to cause damage as seen in nephrolithiasis, but rather grow in
place to damage the nephrons12.
While some treatments for these calcium homeostasis disorders exists, they are
limited in their efficacy, and the vast majority do not directly target proteins involved in
calcium handling. One protein of potential interest for future treatments is transient
receptor potential vanilloid 5 (TRPV5), an ion channel directly involved in systemic
calcium homeostasis that has been shown to be a critical component of calcium
handling in the kidney.
1.2 Transient Receptor Potential Vanilloid 5 (TRPV5)
The transient receptor potential vanilloid 5 (TRPV5) channel formerly known as
epithelial calcium channel 1 (ECaC1) is intimately connected to the calcium homeostasis
machinery as it acts as the regulatory step in renal calcium reabsorption. TRPV5 is
expressed predominately in the distal convoluted tubule (DCT) and connecting tubule
(CNT) in the nephron of the kidney13. It is a highly calcium selective ion channel present
in the apical plasma membrane of these epithelial cells. TRPV5 is an inwardly rectifying
calcium (Ca2+) channel with a reported full conductance state of 59 pS and a
subconductance state of 29 pS at pH 7.4 with Na+ as a charge carrier13. Selectivity of
TRPV5 for Ca2+ over Na+ has been reported to be >100 (PCa:PNa) and the cation
selectivity profile for TRPV5 is Ca2+ > Mn2+ > Ba

2+

= Sr2+ 13. Thus, under physiological

conditions TRPV5 is exclusively permeated by Ca2+.
TRPV5 is a member of the transient receptor potential (TRP) superfamily of ion
channels. The mammalian TRP family is composed of six subfamilies: classical (TRPC),
3

ankyrin (TRPA), vanilloid (TRPV), melastatin (TRPM), polycystin (TRPP), and mucolipin
(TRPML). TRP channels were first discovered in Drosophila photoreceptors14. The
family earned the name “transient receptor potential” because a mutation in the originally
discovered gene created irregularities in the Drosophila electroretinogram wherein
during bright illumination, the receptor potential returned to baseline faster than wildtype,
rendering the trp mutant flies blinded in bright light conditions14. The mammalian TRP
channels are assigned to this family due to their sequence homology to the original
Drosophila trp gene with the TRPC channels having the highest sequence homology of
the superfamily15. TRPV5 is a member of the vanilloid subfamily named for TRPV1, the
first and most extensively characterized of the subfamily, which is activated by vanilloids
such as capsaicin15.
Of the six members of the vanilloid subfamily, TRPV1-4 are considered
ThermoTRP channels in that they are predicted to be gated by heat15. TRPV5 and
TRPV6 have not been shown to be gated by vanilloids or heat and are unique not just
among their subfamily, but also within the entire mammalian TRP channel superfamily
for their extremely high calcium selectivity16. These two channels share ~80% sequence
identity with each other and less than 50% sequence identity with the rest of the
subfamily16. In spite of the similarity of these channels they appear to have distinct roles
in the body. TRPV6 is expressed throughout the body, but it is most abundantly found in
the intestines where it has been shown to be the entry point for Ca2+ absorption16. On
the other hand, TRPV5 is expressed almost exclusively in the kidney where its primary
role is the fine-tuning regulator for calcium reabsorption and excretion16.
The critical role of TRPV5 within the systemic calcium homeostasis machinery is
best exemplified in the TRPV5 knockout mice2. While these mice did not show any overt
4

phenotype with typical life span, weight and behavior, calcium handling abnormalities
were seen in these mice including extreme calcium wasting, reportedly up to six times
that seen in wildtype mice even when fed a calcium-deficient diet2. Interestingly, this
level of hypercalciuria did not result in kidney stones due to the equally extreme polyuria
and urine acidification seen in the knockout mice2. Additionally, serum calcium levels in
the knockout mice remained within normal parameters likely due to the reported
increase in intestinal calcium absorption and reduced bone thickness2.
In humans many polymorphisms in the TRPV5 channel have been reported to
correlate with calcium homeostasis disorders, but only some have been shown to
directly affect TRPV5 single channel activity16-19. The L530R variation, for example, has
been reported to eliminate calcium conduction through TRPV518. Although there are no
reported cases of humans homozygous for this mutation, people with a single copy of
the mutated gene are reported to be at a higher risk for recurrent kidney stones18. The
A563T mutation on the other hand was shown to significantly increase single channel
activity and is correlated to a decreased prevalence of kidney stones in African
Americans19. Interestingly, both of these mutations are located in the S6 and pore
helices of TRPV5. Though these residues are not found directly in the ion conduction
pathway, they are located close enough to the channel pore to potentially disrupt the
architecture.
The endogenous regulation of TRPV5 has been well studied due to its prevalent
role in calcium homeostasis (Figure 1.1). TRPV5 expresses in the apical plasma
membrane of DCT-CNT epithelial cells, exposing the extracellular portion of TRPV5 to
the lumen of the nephron20. From this position, TRPV5 allows Ca2+ to flow along its
concentration gradient into the cytoplasm where the ions are sequestered by calbindin5

D28K to keep the intracellular concentration of Ca2+ stable and not interfere with other
Ca2+ dependent processes in the cell20. Calbindin-D28K then transports the Ca2+ imported
by TRPV5 to the basolateral membrane of the cell where it is exported via the plasma
membrane Ca2+-ATPase (PMCA 1b) and the Na+/Ca2+ exchanger (NCX1) into the
blood20.
Due to its role in the overall regulation of calcium reabsorption, TRPV5 is tightly
controlled by hormones such as PTH and 1,25-(OH)2D3. Both of these hormones
activate pathways that modulate TRPV5-mediated reabsorption of Ca2+ by altering the
concentration of phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) in the membrane or
by changing the concentration of TRPV5 at plasma membrane via endocytosis13. TRPV5
is efficiently recycled therefore few modulators that alter TRPV5 expression have been
uncovered. Rather, most reported regulators of TRPV5 affect plasma membrane
abundance or single channel activity13,20.
Two well characterized modulators of TRPV5 that endogenously affect TRPV5
single channel activity are PI(4,5)P2 and calmodulin (CaM)20. PI(4,5)P2 is a phospholipid
abundantly expressed in the inner leaflet of the plasma membrane. Many TRP channels
are modulated by PI(4,5)P2 in some way, be it activation or inhibition by this
phospholipid15,21. For TRPV5 and its close homologue TRPV6, PI(4,5)P2 has been
shown to bind and robustly activate the channels which causes both to be constitutively
active in vivo13. While the effect of PI(4,5)P2 on TRPV5 is well characterized, the exact
binding site and the molecular mechanism by which PI(4,5)P2 opens the pore of TRPV5
had remained unclear.
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The well characterized endogenous inhibitor of TRPV5, CaM is a ubiquitously
expressed sensor for intracellular calcium levels. CaM acts as a negative feedback
mechanism for TRPV5 where in high calcium concentrations that exceed the
sequestering capabilities of calbindin-D28K activate CaM and cause it to inhibit TRPV520.
This negative feedback mechanism acts to ensure cell viability in extreme
circumstances. While the binding site of CaM to TRPV5 has been investigated using
mutagenesis and NMR spectroscopy, there have been several conflicting models
hypothesized for the exact mechanism of TRPV5 inhibition by CaM22,23. It is well
understood that CaM can undergo conformational changes in the presence and absence
of Ca2+ but how these conformational changes affect binding and inhibition of TRPV5
had not been well characterized. Additionally, this single channel modulation by CaM
was also expected to be conserved between TRP channels as many are modulated by
calcium-bound CaM.
Other endogenous modulators of TRPV5 that have been shown to affect single
channel activity include phosphorylation by protein kinase A (PKA) and binding of
protons due to changes in pH. TRPV5 activation by phosphorylation is thought to be the
method by which changes in PTH alter TRPV5 activity and thus calcium reabsorption in
the kidney. This PTH induced phosphorylation has been shown to be mediated by both
PKA and PKC13. While PKC has been generally shown to alter TRPV5 plasma
membrane concentration, phosphorylation by PKA has been shown to increase the
single channel activity of TRPV524. TRPV5 has also been reported to be gated by both
intracellular and extracellular changes in pH.

Specifically, it has been shown that

TRPV5 is inhibited by low pH (<6.0) in both the extracellular and intracellular space13.
This is hypothesized to be mediated by a pH dependent increase in magnesium (Mg2+)
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blockade as well as direct binding of protons to the channel13. High pH has also been
reported to increase TRPV5 mediated Ca2+ uptake13. The extracellular proton sensors
on TRPV5 are Glu522 and Glu535 which were reported to decrease estimated pore
diameter upon a decrease in pH13. The intracellular proton sensor was found to be
Lys607 which also is expected to induce changes in pore conformation to affect ion
permeation of TRPV513.
Currently there are very few exogenous modulators of TRPV5 including
econazole, miconazole, and select cannabinoids, none of which are selective for TRPV5
over other TRP channels. The lack of specific modulators, activators in particular, for
TPRV5 has limited the ability to study the direct role this channel plays in disease
models. Econazole and similar imidazole derivatives are commonly used as topical
antifungal treatments and have a history of being potent store operated calcium (SOC)
channel blockers25. These compounds were the first exogenous organic molecules
found to modulate TRPV5 with econazole being the most potent with reported IC50
values in the low mircomolar range26,27. However, econazole has limited utility as an
exogenous modulator of TRPV5 due to its ability to inhibit many Ca2+ permeable ion
channels and its poor solubility in aqueous solutions.
Over the last decade cannabinoids have been gaining traction as potential
therapeutics, especially with the FDA approval of cannabidiol (CBD) for use in treating
epilepsy28. TRP channels in particular have been shown to be affected by cannabinoids
to the extent that some have been deemed “ionotropic cannabinoid receptors”29.
Recently two cannabinoids, Δ9-tetrahydrocannabivarin (THCV) and 11-hydroxy-THCV
(THCV-OH), have been found to be modulators of TRPV5 and its close homologue
TRPV630. THCV was reported to be a reversible inhibitor of rabbit TRPV5 with an IC50 of
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4.8 µM30. On the other hand, THCV-OH, the main metabolic derivative of THCV, was
reported to activate the zebrafish orthologue of TRPV5 (drTRPV5/6)30. Neither of these
compounds, however, were selective for TRPV5 over TRPV630. Similarly, the few other
exogenous modulators of TRPV5 that have been reported such as ruthenium red and
TH-1177 lack the potency and specificity for use in targeting TRPV5 in in vivo systems
or for use as scaffolds for drug design26,31.
The diversity of modulators that affect TRPV5 single channel activity make it an
ideal candidate for thorough structural investigation. At the start of this graduate work, no
structural information for the full length TRPV5 channel was available. As a membrane
protein, TRPV5 has the potential to resist crystallization and exceeds the practical limit
for analysis by NMR. Therefore, structural investigations here were performed using the
technique known as cryo-electron microscopy or cryo-EM.
1.3 Cryo-electron Microscopy (cryo-EM)
Cryo-EM is a technique that has evolved rapidly over the last several years. In
particular, single-particle cryo-EM has pushed the limits of the method such that highresolution structures are now possible. Pioneers of this field won the 2017 Nobel Prize in
Chemistry for the development of cryo-EM. The foundation of this technique involves
freezing an aqueous sample of purified protein in liquid ethane. The properties of liquid
ethane allow for such rapid freezing of the solution that the water does not crystallize
and instead becomes an amorphous glass-like solid with protein embedded in it. These
protein molecules are oriented completely randomly within the ice and therefore, imaging
this frozen sample using an electron beam will theoretically produce every possible
orientation of the protein of interest. By using sophisticated reconstruction software,
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these protein images can be reconstructed into a 3D density map that is representative
of the protein in real-space32.
This technique fills the critical gap in structural biology for proteins or complexes
that are difficult or impossible to solve using X-ray crystallography and too large for NMR
spectroscopy. In particular, the TRP channel field has benefited remarkably from cryoEM. In the last half decade, more than half of the 28 mammalian TRP channels have
been solved using cryo-EM. This can be compared to only three TRP channels that were
able to be solved using X-ray crystallography. For membrane proteins in general,
producing crystals that are suitable for crystallography has remained challenging. This
appears to be due to the method of purification which requires the solubilization of the
membrane protein in a detergent micelle. These lipid structures are oriented randomly
and resist crystal packing. On the other hand, for cryo-EM, this random micelle tends to
be beneficial because during the reconstruction process all random or disordered
regions are averaged out meaning that this detergent ring is rendered invisible at atomic
or near-atomic resolution.
The popularity of cryo-EM in recent years has been due to the latest
advancements in cryo-EM technology which transformed it from the ‘blob-ology’ seen in
the 1990’s and early 2000’s to the Nobel Prize-winning technique it is today33. While
most of the hardware used in a typical electron microscope has not changed drastically
since its original design, there are three key upgrades that have created the machine
used today for high resolution structural biology. The first issue to overcome was
stabilizing the vacuum inside the column of the microscope. This was essential because
once a sample is placed in the column for imaging it is exposed to an electron beam.
This electron beam can only function properly if there are no other atoms in the column
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that could cause the electrons to scatter before reaching the sample34. Therefore, the
better and more stable the vacuum, the better the image a microscope can take.
The second large modification to the typical electron microscope used for high
resolution imaging is what is called the auto-loader or auto-loading mechanism. This
technology changes how a sample is placed into the column of the microscope. Sideentry microscopes require that for each sample, a piece of the microscope called the
sample holder is removed completely from the microscope by the user. On the other
hand, the auto-loader allows for the user to insert up to 12 samples at a time. This autoloader technology is a two-fold benefit as the vacuum is not disrupted every time the
sample holder is removed which could affect image quality and it allows for a decrease
in sample drift over time. Samples in a side-entry microscope are accessible to the user
for quick and easy sample removal, but this comes at a cost as the sample is also
exposed to the vibrations in the room which can cause the sample to move over time.
Auto-loaders allow the samples and sample holder to remain completely inside the
microscope at all times which minimizes drift and vibration which in turn allows for a
higher resolution image.
The final and arguably the most important hardware modification seen in the
cryo-EM field is the development of the direct electron detector. Originally, cryo-EM
images were taken using film which could directly interact with the electrons and after
developing the film, the images could be scanned into the computer and analyzed34.
While this is method allows high resolution imaging because film reacts directly with
electrons and is not limited by pixels, it is critically limited based on throughput. The
direct electron detectors in use today keep the benefits of film like the direct interaction
with electrons and take the technology a step further. With direct electron detectors we
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are able to take movies instead of static images, which allows for the averaging of
frames to account for any movement of the particles caused by the electron beam.
Additionally, the direct electron detectors increase throughput drastically from tens of
images per day with film to thousands of images on a direct detector. These new
cameras also skip the development step required for film. Overall, this advancement has
pushed the practical resolution achievable by cryo-EM to into the high resolution range.
It has also been argued that the voltage of the microscope is critical for high
resolution imaging, but some groups have been able to solve high resolution structures
on as low as 200kV microscopes with the other advancements listed above35. Therefore,
while it is typical and recommended for high resolution structures to be solved with a
300kV microscope, which produces a brighter beam and therefore higher contrast
images, it does not appear to be essential.
Another critical advancement in the field of cryo-EM has been the development
of software that transforms the 2D movies produced by a direct electron detector into a
3D density map. These software programs have been developing in tandem with the
hardware changes and have also significantly contributed to the high-resolution
capabilities of cryo-EM. Highlights from the abundant software packages include the
ability to take a movie composed of tens of frames and average it into a single image
that has been corrected for beam-induced motion and the ability to take a
heterogeneous population of protein and solve multiple structures to high resolution36,37.
With enough images, these algorithms can sort, classify and resolve multiple states of a
single protein that allows for one sample to answer many biological questions at a time.
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These advancements in cryo-EM have amounted to what is referred to as the
“Resolution Revolution” which has culminated in an exponential increase in atomic and
near-atomic resolution structures, many are of proteins that we have never seen
before38. The resolutions now achievable using cryo-EM have opened the door for
structure based drug discovery, lead compound optimization, rational drug design and
countless other structure based experiments. For this project in particular, cryo-EM has
opened the door for atomic and near-atomic investigations of an abundance of
mechanisms for TRPV5 gating and modulation.
1.4 Current Study
The lack of structural information regarding TRPV5 prompted us to investigate
TRPV5 using cryo-EM. Additionally, based on the involvement of TRPV5 in a variety of
calcium homeostatic disorders this ion channel is a potential target for drug discovery.
In Chapter 2, we report the first structure ever determined of the TRPV5 channel.
Here, it was solved in the presence of an exogenous inhibitor known as econazole. This
structure along with the previously reported structure of TRPV6, the close homologue of
TRPV5, solved in its apo state allowed us to propose a mechanism of channel
modulation by this inhibitor.
In Chapter 3, we investigate the endogenous modulation of TRPV5. This was
accomplished by solving the structure of an apo state TRPV5 channel as well as the
structures of TRPV5 bound to its exogenous modulators PI(4,5)P2 and CaM. From these
structures and the corresponding functional analyses, we were able to elucidate the
mechanism of action for each of these modulators.
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Based on the structural information accumulated in Chapters 2 & 3, we utilized
structural-based virtual screening to identify novel compounds that modulate TRPV5.
These compounds showed high potency for TRPV5 and one compound exhibited
selectivity for TRPV5 over TRPV6. Functional and structural characterization of these
compounds allowed us to identify two novel binding sites for TRPV5 modulators. These
findings are presented in Chapter 4.
Finally, Chapter 5 includes a summary of the body of work presented here in
context with the larger fields of TRP channel biology and cryo-EM. Additionally, it
examines outstanding questions regarding TRPV5 that could be answered using cryoEM and outlines what new questions we can now ask based on this body of work.
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1.5 Figures

Figure 1.1. Endogenous environment of TRPV5 and select modulators. Diagram
representation of the role of TRPV5 in the cell and a summary of modulators known to
alter single channel activity. Proteins involved in calcium reabsorption in the distal
convoluted tubule (DCT) and connecting tubule (CNT) of the nephron include TRPV5 as
the apical gate, calbindin-D28K as a calcium sequestering mechanism and the plasma
membrane Ca2+–ATPase (PMCA 1b) and the Na+/Ca2+ exchanger (NCX1) as the
basolateral export mechanisms. Modulators of TRPV5 include the organic inhibitor
econazole, protons (H+), calmodulin, protein kinase A and C (PKA, PKC) and
phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2).
15

CHAPTER 2: STRUCTURAL BASIS OF TRPV5 CHANNEL INHIBITION BY
ECONAZOLE REVEALED BY CRYO-EM
Taylor E.T. Hughes1, David T. Lodowski1,2, Kevin W. Huynh1,3, Aysenur Yazici4, John Del
Rosario4, Abhijeet Kapoor5, Sandip Basak6, Amrita Samanta1,6, Xu Han1, Sudha
Chakrapani6, Z. Hong Zhou3, Marta Filizola5, Tibor Rohacs4, Seungil Han7, Vera Y.
Moiseenkova-Bell1,6

1

Department of Pharmacology, School of Medicine, Case Western Reserve University,
Cleveland, Ohio, USA
2

Department of Nutrition, School of Medicine, Case Western Reserve University,
Cleveland, Ohio, USA
3

California NanoSystems Institute, University of California, Los Angeles, California, USA

4

Department of Pharmacology, Physiology and Neuroscience, New Jersey Medical
School, Rutgers University, Newark, New Jersey, USA
5

Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai,
New York, NY, USA
6

Department of Physiology and Biophysics School of Medicine, Case Western Reserve
University, Cleveland, Ohio, USA
7

Pfizer Research and Development, Groton, Connecticut, USA

Corresponding author: V.M.-B. (vxm102@case.edu and
vmb@pennmedicine.upenn.edu)

Originally published in Nature Structural & Molecular Biology:
Jan 2018. Volume 25, pg. 53-60

16

2.1 Abstract
The transient receptor potential vanilloid 5 (TRPV5) channel is a member of the
transient receptor potential (TRP) channel family, which is highly selective for Ca2+,
present primarily at the apical membrane of distal tubule epithelial cells in the kidney and
plays a key role in Ca2+ reabsorption. Here we present the structure of the full-length
rabbit TRPV5 channel as determined by cryo-EM in complex with its inhibitor,
econazole. This structure revealed that econazole resides in a hydrophobic pocket
analogous to that occupied by phosphatidylinositides and vanilloids in TRPV1,
suggesting conserved mechanisms for ligand-recognition and lipid-binding among TRPV
channels. The econazole-bound TRPV5 structure adopted a closed conformation with a
distinct lower gate that occludes Ca2+ permeation through the channel. Structural
comparisons between TRPV5 and other TRPV channels, complemented with molecular
dynamics (MD) simulations of the econazole-bound TRPV5 structure, allowed us to gain
mechanistic insight into TRPV5 channel inhibition by small molecules.
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2.2 Introduction
Nephrolithiasis, commonly known as kidney stones, is a common disease that
affects approximately 30 million Americans39. The occurrence of kidney stones in the
United States has been rising over the last decade39. One of the most critical risk factors
is hypercalciuria, or high levels of calcium (Ca2+) in urine40. Around 80% of all kidney
stones are comprised primarily of Ca2+ salts40. TRPV5 is a highly Ca2+ selective, kidney
specific TRP channel that plays a major role in systemic calcium homeostasis13. TRPV5
is found in the apical membrane of the nephron epithelium and allows for Ca2+
reabsorption from the urine along its concentration gradient13. Loss or dysfunction of
TRPV5 has been shown to severely increase urine Ca2+ levels and the occurrence of
kidney stones13,41.
TRPV5 belongs to the TRPV subfamily of TRP channels that contains six
members (TRPV1-TRPV6)15. In the TRPV subfamily, TRPV5 and TRPV6 are the only
Ca2+ selective channels and share high sequence identity13,42. In the absence of
modulators, TRPV5 and TRPV6 are constitutively active channels13. Several
endogenous modulators such as calmodulin (CaM) and phosphatidylinositol 4,5bisphosphate (PI(4,5)P2) have been found to stabilize these channels in the closed or
open conformation, respectively43,44. Additionally, the small molecule antifungals
econazole and miconazole, which are commonly used topically to treat skin infections,
have been shown to effectively inhibit both TRPV5 and TRPV613,26. While TRPV6 has a
wide tissue distribution42,45, TRPV5 expression is limited to the kidney13 where it plays a
key role in Ca2+ reabsorption in the human body13.
No atomic structures for TRPV subfamily members were available until the
recent revolution in the cryo-EM field enabled the first atomic structure determinations
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for TRPV1 and TRPV246-48. Subsequently, other TRP channels structures have been
determined using cryo-EM, which have revealed structural diversity among family
members49-53. The X-ray structures of modified and truncated TRPV6 constructs have
also been solved54,55, which suggested a mechanism of Ca2+ permeation, but did not
provide information regarding ligand binding, modulation and channel gating. Prior to our
work, the atomic structure of full-length TRPV5 and how small molecules modulate
TRPV5 at molecular level had remained unknown.
Here, we report a cryo-EM structure of the full-length TRPV5 channel in the
presence of econazole at a resolution of 4.8Å, with the local resolution at the
transmembrane (TM) region of the channel resolved to 3.5-4.0Å. This full-length TRPV5
structure revealed that, like other TRPV subfamily members46-48, the channel adopts a
domain-swapped architecture which is common to many voltage-gated ion channels56.
The structure depicts the inhibited state of the TRPV5 channel and allows for the
identification of a putative binding site for econazole. Based on currently available
structural information for TRPV channels combined with energy refinements of the
econazole-bound TRPV5 structure in a membrane-mimetic environment by molecular
dynamics (MD) simulations, we have gained the first insight into the mechanism of
TRPV5 inhibition.
2.3 Results
Determination of the inhibitor bound TRPV5 structure
The full-length rabbit TRPV5 channel was heterologously expressed using S.
cerevisiae

and

purified

using

established

(Supplementary Figure 2.1A)46,57-59.

and

previously

published

protocols

Rabbit TRPV5 has high sequence homology to

human TRPV5 (>80%), particularly in the pore region and was favorably expressed in
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our system (Supplementary Figure 2.1A). To investigate the structure of full-length rabbit
TRPV5 in the presence of econazole we utilized cryo-EM, which allowed us to image
TRPV5 in an aqueous environment and avoid potential artifacts of protein crystallization,
such as crystal packing that may not be biologically relevant.
We determined that the econazole half-maximal inhibition (IC50) was 2 μM for
rabbit TRPV5 in HEK293 cells (Supplementary Figure 2.1B-C), which is similar to that
reported earlier (IC50 1.3 μM)26. Detergent solubilized rabbit TRPV5 was frozen in
vitreous ice in the presence of 6 μM econazole. This concentration of econazole is three
to four times higher than the IC50 values reported by our group (Supplementary Figure
2.1C) and by others in mammalian cells26. This was the highest concentration we could
achieve while minimizing the effect of dimethyl sulfoxide (DMSO) on freezing conditions
and taking into account the limit of econazole solubility.
The overall resolution of the cryo-EM TRPV5 density map (TRPV5ECN) was 4.8Å
with the local resolution in the transmembrane (TM) region between 3.5-4Å. This
structure was reconstructed from one 3D class that contained 50,566 particles using
RELION 2.060,61 (Figure 2.1A, Table 2.1, Supplementary Figure 2.1D-E, and
Supplementary Figure 2.2). The number of particles that went into the final
reconstruction is in line with recently published TRPV1 channel structures with various
ligands62,63 and we believe that the other 3D classes from this dataset represent poor
quality TRPV5 particles. The quality of the cryo-EM densities in the TM region allowed
us to confidently build an atomic model of this portion of the protein (Supplementary
Figure 2.2, Supplementary Figure 2.3). The N-terminal ankyrin repeat domain (ARD) and
C-terminus were resolved in the range of 4-5.5Å, which allowed for model building in this
region and the fitting of a TRPV5 ARD homology model based on the TRPV6 ARD
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structure64 (Supplementary Figure 2.2, Supplementary Figure 2.3). The final overall
TRPV5 structural model (TRPV5ECN) is presented in Figure 2.1B.
Overall TRPV5 channel architecture
All recently determined cryo-EM structures of TRP channels revealed a domainswapped architecture, also shared by many voltage-gated ion channels46-53. As
expected, the full-length TRPV5 structure is similar to other TRPV subfamily structures
(Figure 2.1A-B)46-48. Specifically, it is a tetrameric ion channel comprised of classic TRPV
channel domains, such as transmembrane helices (S1-S6), an N-terminal ARD, a linker
domain, and the C-terminal TRP domain (Figure 2.1B). While our construct was a fulllength TRPV5, we only were able to resolve ~85% of the total protein (Trp29-His637)
due to the N-terminal and C-terminal flexibility (Figure 2.1B). The loop region between
S1 and S2 (Arg355-Ala376) was also not resolved (Figure 2.1B). The loop between S2
and S3, which was not resolved in the structures of the close homologue, TRPV654,55,
was resolved in our TRPV5 structure. This region resembles that of TRPV1 and TRPV2.
Additionally, two non-protein densities adjacent to each TM domain of the
channel were observed in the structure (Figure 2.1C-D). One was clearly visible between
the S1 and S2 helices and was assigned to a tightly bound lipid molecule (Figure 2.1C,
Supplementary Figure 2.4A). This density is in an analogous position to the lipid
densities that have been found in previously published TRPV1 and TRPV2 structures
resolved in amphipol and nanodiscs48,63 (Supplementary Figure 2.4A). TRPV5 was
imaged in the presence of decyl maltose neopentyl glycol (DMNG) detergent, which
suggests that this tightly bound lipid is preserved independently of the sample
preparation method. Based on the shape of this density and the densities in published
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results for other TRPV channels, we have assigned this density to phosphatidylcholine
(Figure 2.1C, Supplementary Figure 2.4A).
The second density was found positioned between S4 and S5 of each subunit
and S6 of the neighboring subunit and was putatively assigned to econazole (Figure
2.1D). The TRPV1 structure with capsazepine is the only other TRPV subfamily member
cryo-EM structure solved in the presence of an inhibitor63 (Supplementary Figure 2.4B).
We compared the position of the econazole density in our TRPV5 structure to the
density assigned to capsazepine in the TRPV1 structure (Supplementary Figure 2.4B).
In both structures, these inhibitors occupied very similar positions, suggesting that this
ligand-binding pocket may be conserved among TRPV channels (Supplementary Figure
2.4B).
Econazole binding pocket
Econazole is an antifungal drug that has been shown to inhibit both TRPV5 and
TRPV6 channels26,31. In our experiments, rabbit TRPV5 was inhibited in the presence of
2 μM econazole when overexpressed in HEK293 cells (Supplementary Figure 2.1B-C).
Purified TRPV5 was frozen in the presence of 6 μM econazole, which is the in upper
concentration range of the published econazole IC50 (1.3 μM)26 and the IC50 (2 μM)
determined by our group for TRPV5 expressed in the HEK293 cell line (Supplementary
Figure 2.1B-C). An econazole molecule (either the R or S enantiomer) can be fit
reasonably well into the assigned cryo-EM density by manual docking (Supplementary
Figure 2.5A-C). Although the low resolution of the structure does not allow us to
unambiguously determine by cryo-EM what enantiomeric form of the drug is bound to
the protein, it appears that the chlorophenyl moiety of R-econazole fits better in the
electron density (Supplementary Figure 2.5A-C). While the chlorophenyl and
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dichlorophenyl moieties of econazole can be docked successfully into the density
(Supplementary Figure 2.5A-C), the density for the imidazole ring was not resolved.
However, this is likely due to the flexible nature of this moiety compared to the rest of the
compound and the current resolution of the cryo-EM structure in this region.
Several residues surrounding the density assigned to econazole were observed
to be within interaction distance of the econazole molecule (minimum distance within 4.0
Å between heavy atoms) and therefore, could be involved in econazole binding
(Supplementary Table 2.1). However, it is of note that not all residues within interaction
distance remained so during molecular dynamics simulations, suggesting some residues
may play a less significant or transient role in econazole binding. Shown in bold in
Supplementary Table 2.1 are residues that stayed within 4.0Å from at least three of the
four econazole molecules during the MD simulations with either enantiomeric form.
These residues have been assigned as the putative econazole binding pocket and
include Phe425 and Ile428 located on the S3 helix, Leu460 and Cys463 located on the
S4 helix, Ile486 from the S4-S5 linker region and Ile565 located on the S6 helix of an
adjacent monomer (Figure 2.2A). Although the relative contribution of these residues to
the free-energy of econazole binding cannot be inferred by simple energy relaxation, the
MD data support the hypothesis that this mainly hydrophobic pocket may recognize and
bind small molecules like econazole and miconazole that inhibit TRPV5 and TRPV6
(Supplementary Figure 2.5D-E).
In order to provide additional evidence that this density is indeed econazole and
that these residues constitute the econazole binding pocket, we utilized the relatively
high throughput Xenopus oocyte two electrode voltage clamp technique and tested the
effect of mutating one residue on each region of the proposed putative binding pocket
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that remained within 4.0 Å from at least three of the four econazole molecules in either
enantiomeric form. Specifically, we tested the effect of Phe425Ala, Leu460Ala, Ile486Ala
and Ile565Ala mutations on TRPV5 inhibition by econazole (Supplementary Figure 2.6).
Consistent with previous observations31, higher concentrations of econazole were
required to achieve rabbit TRPV5 inhibition in Xenopus oocyte compared to the HEK293
expression system. In Xenopus oocytes we used 20 µM econazole, which resulted in
~40% inhibition of the wildtype channel (Figure 2.2B, 2.2D). Among tested mutants, the
Phe425 to Ala425 mutation showed a significantly reduced inhibition by econazole
(Figure 2.2C-D), implying the involvement of this residue in the binding of econazole.
The other tested alanine mutations (Leu460Ala, Ile486Ala and Ile565Ala) did not reduce
the inhibitory effect of econazole on TRPV5 (Supplementary Figure 2.6). Ile486Ala and
Ile565Ala were inhibited more than the wild-type TRPV5, but those mutants also
displayed some inhibition by DMSO at the concentration necessary dissolve econazole
(Supplementary Figure 2.6), implying that processes other than econazole binding may
be involved. Overall it is likely that the Leu460, Ile486, and Ile565 residues do not
contribute to econazole inhibition to the same extent as Phe425.
The econazole-binding pocket in TRPV5 resembles the “vanilloid”-binding pocket
that was identified in TRPV1 by cryo-EM63 (Supplementary Figure 2.7). The TRPV1
“vanilloid”-binding pocket can accommodate activators (resiniferatoxin and capsaicin), as
well as inhibitors like capsazepine and modulators of channel activity such as
phosphatidylinositol lipids63 (Supplementary Figure 2.7). It has been proposed that the
exchange between phosphoinositides and the TRPV1 activators and inhibitor in this
“vanilloid”-binding pocket allosterically regulates TRPV163. Moreover, the “vanilloid”
insensitive TRPV2 channel can be transformed into the “vanilloid” sensitive channel by
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modification of 4 critical residues in this “vanilloid”-binding pocket65,66. One of these
residues is located on the S3 helix: for mouse TRPV1 it is a polar Ser513 and for mouse
TRPV2 it is a hydrophobic Phe467 (Figure 2.2E-F). Changing of the TRPV2 Phe467 to
Ser467 facilitates capsaicin entering into the “vanilloid”-binding pocket of TRPV265,66.
Change of TRPV1 Ser513 to Tyr513, a residue that is equally bulky as Phe467 in
TRPV2, diminishes TRPV1 activation by capsaicin65,66. The S3 helix of rabbit TRPV5
harbors Phe425 at the same position as mouse TRPV2 Phe467 (or rabbit TRPV2
Phe470) (Figure 2.2E) and mouse TRPV1 Ser513 (Figure 2.2F). Intriguingly, like
TRPV2, TRPV5 does not respond to capsaicin or capsazepine26, suggesting that
presence of the hydrophobic Phe at this position may prevent these TRPV1 specific
modulators from entering the TRPV5 ligand-binding pocket, but could allow for the
interaction with its specific modulators via a mechanism similar to that seen for TRPV2
vanilloid insensitivity65,66.
Additionally, our MD simulations of the econazole-bound TRPV5 tetramer also
suggested high flexibility of the drug within the binding pocket of the TRPV5 subunits
(2.0-6.4 Å RMSD for R-econazole and 1.9-7.2 for S-econazole; Supplementary Figure
2.8) while the TRPV5 tetramer kept its overall conformation during 25 ns MD (average
Cα RMSDs of the TM helices is 2.3 ± 0.1 Å for the protein bound to R-econazole and 1.9
± 0.1 Å for the protein bound to S-econazole with respect to the initial structure derived
from the electron density map; Supplementary Figure 2.9A and 2.9C). As also seen in
simulations of TRPV1 bound to either antagonists or agonists67, the four monomers in
the TRPV5 tetramer show different dynamic behavior as evident from comparison of
their Cα root-mean-square fluctuations (RMSF; Supplementary Figure 2.9B and 2.9D),
where peaks correspond to loop regions. The initial identical poses of econazole in the
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four monomers of the TRPV5 tetramer differ during dynamics with ECN_1 and ECN_2
molecules of both R-econazole and S-econazole fluctuating more than ECN_3 and
ECN_4 during the production run (Supplementary Figure 2.8 and 2.10). This differential
flexibility of the econazole molecules within the binding pockets may be dependent on
the

surrounding

environment.

Interestingly,

the

number

of

1-palmitoyl-2-oleoyl

phosphatidyl choline (POPC) molecules in contact with each of the 3 ring moieties of
econazole (i.e., chlorophenyl, dichlorophenyl, and imidazole) shows moderate to strong
correlation with the RMSD of the most fluctuating econazole molecules during the
production run (correlation coefficients are 0.53 and 0.46 for the ECN_1 and ECN_2 Rmolecules, respectively, and 0.7 and 0.68 for the corresponding S-molecules), but much
lower correlation with the two econazole molecules that move less (ECN_3 and ECN_4),
suggesting a direct effect of lipid contacts on the flexibility of the econazole molecules.
TRPV5 ion permeation pore in the presence of econazole
TRPV5 and TRPV6 are Ca2+ selective non-voltage-gated ion channels that
belong to the TRP family of proteins15. The ion permeation pore of the econazole-bound
TRPV5 is comparable to other TRPV channels, which is formed between the S5 helix,
the P-helix loop, and the S6 helix (S5-P-S6) (Figure 2.3A-B). Nevertheless, TRPV5 is a
Ca2+ selective channel and unique pore features are noted in the structure. Four aspartic
acid residues (Asp542), one from each monomer, line the selectivity filter of the channel
and coordinate Ca2+ ions. In fact, a density possibly corresponding to a Ca2+ ion along
the central pore axis was resolved in our econazole-bound TRPV5 structure (Figure
2.3C). The carboxylate groups of Asp542 are not clearly resolved in the EM map due to
radiation damage (Supplementary Figure 2.3A), however the quality of the cryo-EM
densities in this region allowed for backbone assignment. The position of the Asp542
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side chain in the TRPV5 pore was selected based on the best-allowed rotameric position
(Supplementary Figure 2.3A).
The ionic diameter of Ca2+ is 2.28 Å and ~10-12 Å when fully hydrated68,69. The
distance between the oxygen atoms of two opposing Asp542 carboxylates in the
selectivity filter, as measured from our model, is ~7 Å, which may require water
molecules to facilitate Ca2+ ion interaction with the filter69. The distance between the
putative Ca2+ ion and carboxylate oxygen atoms of the Asp542 residues in our model
(Figure 2.3D, represented by the dash lines) is 3.5 Å, suggesting that the density
represents a partially hydrated Ca2+ ion coordinated by the selectivity filter (Figure 2.3CD). Moreover, the extracellular vestibule of the TRPV5 pore is predominantly
electronegative (Figure 2.3E), suggesting that it directs Ca2+ ions towards the selectivity
filter. In our MD simulations, a Ca2+ ion remains stably coordinated by the four Asp542
residues along with one (in the R-econazole bound TRPV5 complex) or up to two (in the
S-econazole bound TRPV5) water molecules, thus maintaining a coordination number of
~7 throughout the simulation. While all four oxygen atoms of the Asp542 carboxylate
moieties on monomers B and C maintain an average minimum distance of 2.9 ± 0.2 Å
from each other in the TRPV5 complex bound to R-econazole and an average ~2.2 Å
distance from the Ca2+ ion, only 2 out of 4 oxygen atoms of the Asp542 residues on
monomers A and D contribute to the Ca2+ coordination through an average minimum
distance of 4.1 ± 0.3 Å from each other and an average distance of ~2.2 Å from the Ca2+
ion. The simulation of TRPV5 bound to S-econazole behaves in a similar manner.
The lower gate of econazole-bound TRPV5 is tightly closed, as expected due to
channel inhibition by this small molecule (Figure 2.3A-B). The inner helical bundle at the
Phe574, Met578, His582 positions constricted the pore to a diameter of ~5.9 Å at the
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Phe574, ~5.3 Å at the Met578 and ~4.5Å at the His582 position (Figure 2.3B and 2.3F).
As previously noted in the TRPV6 structure, Met577 is the key residue involved in
channel closure54,55 (Figure 2.4A). In our current TRPV5 model, His582 is the narrowest
point in the pore (Figure 2.3F, Figure 2.4B). However, our 25 ns MD simulations, during
which these residues move to average minimum distances above 9 Å, did not support
this assessment. While both Phe574 and Met578 residues on monomers A and D
maintained a 4.0 ± 0.4 and 4.1 ± 0.4 Å average minimum distance, respectively,
between side chain heavy atoms of TRPV5 bound to R-econazole during MD
simulations, the two residues on monomers B and C assume an average minimum
distance of 7.8 ± 0.4 and 7.2 ± 0.5 Å respectively. Taken together, our data suggest that
the pore of the econazole-bound TRPV5 is non-conducting as both Phe574 and Met578
residues might obstruct Ca2+ flow. A similar dynamic behavior is seen in the TRPV5
complex bound to S-econazole.
While TRPV5 and TRPV6 share high levels of sequence homology, we noted
several differences in the pore architecture between full-length rabbit TRPV5 and the
modified rat TRPV6 (TRPV6*) employed in its structural studies55 (Figure 2.4A-B).
Specifically, the first residue that constricts the TRPV5 pore is Phe574, which is
conserved between rabbit, rat and human TRPV5, but diverges to Leu573 in rabbit, rat
and human TRPV6 (Figure 2.4A-B). While both side chains are hydrophobic, the
observed difference in the level of pore obstruction at this amino acid position is due to
the size difference between Phe and Leu (Figure 2.4A-C). Another notable difference
was at the position of Met578 in rabbit TRPV5 versus Met577 in rat TRPV6* (Figure
2.4A-B). While in both channel structures the Met residues create constricted region in
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the pore (Figure 2.4A-B), the positions of the Met side chains are distinct for each
structure (Figure 2.4A-B).
The major difference noted between the full-length rabbit TRPV5 and the rat
TRPV6* structures was at the selectivity filter (Figure 2.4A-B). The side chain of Asp541
in rat TRPV6* projects towards the pore (Figure 2.4A), while the position of the
analogous Asp542 side chain in rabbit TRPV5 structure resembles that of voltage-gated
Ca2+ channels68,69 (Figure 2.4B, Figure 2.4C-D). The distance between the center of the
oxygen atoms from two opposing Asp541 in the rat TRPV6* which coordinate Ca2+ at the
selectivity filter is 4.6 Å, suggesting that an Asp from each subunit binds dehydrated
Ca2+ 54(Figure 2.4E). While we could not completely resolve the side chain of Asp542 in
rabbit TRPV5, our model and MD data suggest that the Asp side chain positions in the
pore could coordinate partially hydrated Ca2+ ion (Figure 2.4F), as it has been proposed
for CavAb and Cav1.1 channels68-70 (Figure 2.4G).
First insight into the mechanism of econazole inhibition of TRPV5
Econazole is a potent inhibitor of TRPV5 and TRPV6 channels, which upon
binding critically affects ion conduction through the channel pore26,31. The high level of
sequence homology between these two TRPV subfamily members as well as their
comparable functional properties has allowed us to propose a mechanism of econazole
inhibition of TRPV5. A mutated and truncated construct of rat TRPV6 (TRPV6*)55 was
solved via X-ray crystallography in the absence of any organic small molecule inhibitor,
and the rabbit TRPV5 structure that is presented here is econazole bound.
Superimposition of these two non-conducting structures revealed several conformational
differences

between

the

unbound

TRPV6*55

and

inhibited

TRPV5

structures

independent of sequence conservation (Figure 2.5). Econazole binding to the
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hydrophobic pocket between the S3-S4 helices, the S4-S5 linker and the S6 helix of the
adjacent subunit appears to have produced a movement of the S1-S4 helical bundle
together with S4-S5 linker away from the pore axis and to have enabled a
conformational change in the loop that connects the S6 helix to the TRP domain (Figure
2.5A). This loop movement causes the constriction of the lower gate, specifically at
conserved residues Phe574, Met578, and His582, thus obstructing the pore (Figure
2.5B). Moreover, this loop movement produced additional conformational changes in the
TRP domain leading to large vertical and rotational motions of the ARDs of the channel
(Figure 2.5C-D). Our structural observation is consistent with a recent mutagenesis
study43, which suggested a very similar gating mechanism for the TRPV5 channel and
implicated His582 in this mechanism.
Intriguingly,

these

econazole-induced

conformational

changes

did

not

significantly affect the conformation of the outer pore region of the TRPV5 channel or its
selectivity filter (Figure 2.5B). This suggests that while gating of some TRPV subfamily
members involves the outer pore region, called the turret region in the case of TRPV162
and TRPV246, TRPV5 and TRPV6 do not require large conformational changes in this
region for channel gating.
2.4 Conclusions
Our cryo-EM structure of the econazole-bound full-length TRPV5 channel
exhibits a domain-swapped architecture, which is a hallmark of all currently determined
TRP channels at atomic resolution46-53 and was recently also confirmed to be present in
TRPV654,55. Our data revealed that overall TRPV5 and TRPV6 are similar, but the
principal structural differences between them could be utilized to further understand the
TRPV subfamily of the channels. The TRPV5 pore architecture suggests that like other
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Ca2+ selective ion channels68-70, it selects Ca2+ ions through interaction with their
hydration shell69 and may not interact with Ca2+ ions directly54,55. Nevertheless, further
studies will be required to better understand the mechanism of Ca2+ ion permeation
through these Ca2+ selective non-voltage-gated channels.
Based on comparisons between the TRPV5 and TRPV6 structures, we were able
to make initial inferences about the mechanism of channel inhibition by econazole
(Figure 2.6). First, we demonstrated that inhibitors of TRPVs interact with the channels
through a conserved hydrophobic ligand-binding pocket (Figure 2.6). Next, we showed
that inhibitor binding to the TRPV5 channel is associated with movements in the S1-S4
helices bundle and S4-S5 linker, which are accompanied by conformational change in
the lower gate of the channel, and may lead to it closure (Figure 2.6). Finally, consistent
with the recent mutagenesis and structural studies43, we determined that in addition to
the Met578, the rotation of the Phe574 and possibly His582 into the pore may further
block Ca2+ ion flow through TRPV5 (Figure 2.6).
Here we presented a structure of the TRPV5 channel in an inhibited state. The
determination of full-length TRPV5 in ligand-free and ligand-activated states will be
essential in understanding the structural diversity between TRPV channels gating
mechanisms and their physiological functions. This study in conjunction with future
findings will potentially pave the way for novel targeted therapies for hypercalciuria and
nephrolithiasis.
2.5 Methods
Protein expression and purification. Full-length wild type rabbit TRPV5 was
expressed with a C-terminal 1D4 epitope (TETSQVAPA) in the BJ5457 S. cerevisiae
strain as previously reported46. In order to maintain protein stability, all purification steps
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were conducted at 4 °C. Cells were lysed via microfluidizer (M-110Y, Microfluidics,
Newton, MA) and plasma membranes were isolated using multiple rounds of
centrifugation (3,000 x g for 10 mins, 14,000 x g for 35 mins, 100,000 x g for 45 mins).
Plasma membranes were stored at -80 °C until needed. To purify the channel, the
plasma membranes were solubilized in a buffer containing 20 mM HEPES pH 8.0, 150
mM NaCl, 0.87 mM LMNG, 5% glycerol, 2 mM TCEP, and 1 mM PMSF for 1 hour. The
sample was then centrifuged at 100,000 x g to remove any insoluble material. The
protein was then bound to an affinity chromatography column containing 1D4 antibody
conjugated CnBr-activated Sepharose 4B beads. The column was washed with a buffer
containing 20 mM HEPES pH 8.0, 150 mM NaCl, 0.064 mM DMNG and 2 mM TCEP
and TRPV5 was eluted using buffer containing 20 mM HEPES pH 8.0, 150 mM NaCl,
0.064 mM DMNG, 2 mM TCEP and 3 mg/mL 1D4 peptide (NH2-TETSQVAPA-CO2H).
Eluted protein was concentrated and further purified by size exclusion chromatography
(Superose 6, GE Healthcare) in 20 mM HEPES pH 8.0, 150 mM NaCl, 0.064 mM DMNG
and 2 mM TCEP. The peak fraction was centrifugally concentrated and used for
subsequent cryo-EM studies. No Ca2+ chelators were included in any of the purification
buffers.
Electrophysiological recordings. Two electrode voltage clamp (TEVC) experiments in
Xenopus oocytes were performed as described previously71. Briefly, ovarian sacs were
removed from female Xenopus laevis frogs, then oocytes were digested using 0.2 mg/ml
collagenase (Sigma) in a solution containing 82.5 mM NaCl, 2 mM KCl, 1 mM MgCl2,
and 5 mM HEPES, pH 7.4 (OR2 solution) overnight for ~16 h at 18 °C in a temperature
controlled incubator. Defolliculated oocytes were selected and kept at 18 °C in OR2
solution supplemented with 1% penicillin/streptomycin (Mediatech) and 1.8 mM CaCl2.
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cRNA was generated from the linearized rabbit TRPV5 and its mutants in the pGEMSH
oocyte vector, using the mMessage mMachine kit (Ambion). RNA, 5 ng was
microinjected into each oocyte using a nanoliter injector system (World Precision
Instruments). The experiments were performed 48 to 72 h after injection. TEVC
measurements were performed as described earlier; briefly oocytes were placed in a
solution containing 97 mM NaCl, 2 mM KCl, 1 mM MgCl2, and 5 mM HEPES, pH 7.4,
where TRPV5 currents are largely blocked by Mg2+ and trace amounts of Ca2+ in the
medium. Monovalent currents were initiated by a solution containing 96 mM LiCl, 1 mM
EGTA, and 5 mM HEPES, pH 7.4. Currents were recorded with thin-wall inner filamentcontaining glass pipettes (World Precision Instruments) filled with 3 M KCl in 1%
agarose. Currents were measured with a ramp protocol from -100 to 100 mV applied
every 500 ms, preceded by a step to -100 mV for 50 ms. Econazole was dissolved in
DMSO as a stock solution at 0.4 mg/ml (0.9 mM). The stock was added directly to the
aqueous buffer solutions for measurements in oocytes. To apply 20 μM of econazole in
the oocyte measurements, the final concentration of DMSO was 2.2%.

Higher

concentrations of DMSO inhibited wild type TRPV5 currents, thus we could not apply
higher concentrations of econazole.
Whole cell patch clamp was performed similar to that described for TRPV671, with some
modifications. HEK293 cells were cultured in MEM supplemented with 10 % FBS, and
kept in a humidified incubator with 5% CO2 at 37C. Cells were transfected using the
Effectene reagent (Qiagen), and measurements were performed 48-72 h after
transfection. Currents were measured with an Axpatch 200B amplifier, using a ramp
protocol from -100 to 100 mV applied every second. The extracellular solution contained
142 mM LiCl, 1 mM MgCl2, 10 mM HEPES and 10 mM glucose, pH 7.4. Monovalent
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currents were initiated by the same solution containing 1 mM EGTA, but no MgCl2. The
intracellular pipette solution contained 140 mM K-gluconate, 10 mM HEPES, 5 mM
EGTA, 2 mM MgCl and 2 mM ATP, pH 7.3. For both oocytes and for HEK cells we used
a LiCl based extracellular solution, because in this solution removal of extracellular Mg2+
and Ca2+ does not induce endogenous currents in non-transfected cells, unlike in Na+ or
K+ based solutions. The econazole stock as described above was added directly to the
aqueous buffer solutions for measurements in HEK cells.
Cryo-EM data collection. Filtered, concentrated TRPV5 (~2.5 mg/mL) was incubated
with 5.6 μM econazole and 3 mM fluorinated Fos-Choline-8, which improved particle
distribution. The sample was double blotted (3.5μL per blot) onto 200 mesh Quantifoil
1.2/1.3 grids (Quantifoil Micro Tools), the second blot was incubated for 30s and the
grid was plunge frozen using a Vitrobot (FEI). The grids were imaged using a 300kV
FEI Titan Krios microscope equipped with a Gatan K2 Summit direct detector camera.
50-frame movies were collected at a nominal magnification of 45,455x in superresolution mode resulting in a pixel size of 0.55Å at sample level and a dose rate of
~8 electrons/pix/s in the detector. Total exposure time for each movie was 10 seconds
with one frame collected every 0.2 seconds. Images were collected 1.5-4.0 μm under
focus as per the automated imaging software, Leginon 72.
Image processing. Movies were motion corrected to compensate for beam-induced
motion using MotionCor2 resulting in summed and dose-weighted micrographs73. The
pre-processing procedures, CTF estimation, and auto-picking procedures were
performed on the summed micrographs and the 2D classification, 3D classification and
3D auto-refinement were performed with the dose-weighted micrographs. The defocus
values of the motion corrected micrographs were estimated using Gctf software74.All
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subsequent data processing was conducted in RELION 2.060,61. Approximately, 2,000
particles were manually picked from the 3,313 micrographs and sorted into 2D classes.
The best of these classes were used as templates for auto-picking. A loose auto-picking
threshold was selected to ensure no good particles were missed. This resulted in
~900,000 auto-picked particles that were subjected to multiple rounds of 2D
classification to remove false positives and suboptimal particles. The best 137,679
particles were then subjected to 3D auto-refinement, followed by 3D classification into 4
classes. A published structure of TRPV2 low-pass filtered to 60Å was used as an initial
model for the first 3D auto-refinement46. Subsequent classifications and refinements
utilized the TRPV5 map from the first 3D auto-refinement low-pass filtered to 60Å as the
initial model. The mask used for processing was created from the TRPV5 map from the
first 3D auto-refinement adjusted to a threshold of 0.005 and lowpass filtered to 15Å.
The best 3D class, containing 70,059 particles, was subjected to an additional round of
3D auto-refinement and 3D re-classification. From this, the best 50,566 particles were
used in the final 3D auto-refinement and post-processing to yield a TRPV5 structure
at an overall resolution of 4.8Å based on the 0.143 cut-off criterion. Local resolutions
were estimated using the RESMAP software75.
TRPV5 model building. An initial homology model was generated with the I-TASSER76
server employing all previous structures of TRPV1 (apo-TRPV1 PDB: 3J5P, capsaicin–
TRPV1 PDB: 3J5R, RTX/DkTx–TRPV1 PDB: 3J5Q), TRPV6 (apo-TRPV6 PDB:5IWK)
and our previous structure of full-length TRPV2 (PDB: 5HI9). This initial model was
aligned to our TRPV5 cryo-EM map calculated with RELION 2.0 and was manually
adjusted to fit the electron density in Coot77. After this initial model fitting, we refined this
model against the EM-derived maps using the phenix.real_space_refinement tool from
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the PHENIX software package78, employing rigid body refinement, gradient minimization,
local grid search and ADP refinement with secondary structure restraints and NCS
constraints. The structures of TRPV1 (PDB: 3J5P, 3J5R, 3J5Q), rabbit TRPV2 (PDB:
5AN8) as well as the new TRPV6* structure (generously provided by Dr. Sobolevsky55)
were used as references during manual building and structure adjustment, and assisted
in assignment of topology and improved connectivity in the model. The model was
subjected to additional rounds of manual model fitting and real space refinement (RSR),
resulting in a final model to map cross-correlation coefficient of 0.722.
Molecular Docking and MD Simulations. Both enantiomers of econazole were
manually docked to fit the assigned cryo-EM density within the four TRPV5 monomers.
The atomic coordinates of the R-econazole-bound or S-econazole-bound TRPV5
tetramer embedded in a 1-palmitoyl-2-oleoyl phosphatidyl choline (POPC) bilayer
solvated with TIP3P water, 0.15 M NaCl, and additional neutralizing ions were used for
MD simulations. Missing residues of the loop between TM helices S1 and S2 (residues
356-375) were added with MODELLER79 using the corresponding region of the TRPV6
crystal structure (PDB id: 5WIP) as a template for homology modeling. A total of 50 loop
models were generated and the structure with the top discrete optimized protein energy
(DOPE)80 score was selected as an initial conformation for the loop. The starting system
for MD simulations was assembled with the Membrane Builder functionality of the
CHARMM-GUI webserver81,82. This system (box dimension: 143 Å x 143 Å x 147 Å)
consisted of the TRPV5 tetramer, R- or S-econazole molecules bound to each tetramer
subunits, 450 POPC molecules, 58,725 to 59,185 water molecules, 213 to 215 sodium
ions, 183 to 185 chloride ions, and a calcium ion in the outer pore region, totaling
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276,224 atoms in the case of TRPV5 bound to R-econazole, and 277,608 atoms for
TRPV5 bound to S-econazole.
MD simulations were run using Gromacs 2016.383 with a timestep of 2 fs for computation
and CHARMM36 force field84-86. Initial parameters for either R- or S-econazole were
obtained using the CHARMM General force field via the ParamChem webserver and
were further validated and optimized following published guidelines87. The system was
first minimized using steepest descent for 5000 steps, followed by 50 ps of NVT and 50
ns of NPT equilibration. The NPT equilibration was performed in 18 steps with the first
17 steps consisting of gradually decreasing positional restraints on the heavy atoms of
lipids first, followed by protein sidechains, protein backbone and ligand ring atoms, and
lastly, the remaining ligand atoms. The last step consisted of a 1 ns unrestrained NPT
equilibration which was followed by a 25 ns production run. During the equilibration,
system temperature and pressure were maintained at 300 K and 1bar, respectively,
using velocity rescale88 for temperature coupling and a Parrinello-Rahman barostat for
pressure coupling. Semi-isotropic pressure coupling was applied during simulation. All
bonds involving H-atoms were constrained using the LINCS algorithm. Short-range
nonbonded interactions were cut at 12 Å. Long-range electrostatic interactions were
computed using the Particle Mesh Ewald (PME) summation with a Fourier grid spacing
of 1.6 Å. The production run was performed with the same parameters as described
above but with the thermostat switched to Nose-Hoover89.
The resulting production trajectory was analyzed using PyEMMA 290 and VMD91. Pymol
(Version 1.8 Schrödinger, LLC) was used to create images. Root mean squared
deviation (RMSD) of the protein Cα atoms and econazole heavy atoms were calculated
following superposition of residues of TM helices S1 to S6 in the trajectory frames onto
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the coordinates of the starting cryo-EM structure. Minimum heavy atom distance
between POPC molecules and each of the three ring moieties (chlorophenyl,
dichlorophenyl, and imidazole) of econazole were calculated for each trajectory frame
using PyEMMA 2, and the number of POPC molecules in contact with each of the rings
of econazole were computed with a minimum heavy atom distance cutoff of 4.5 Å.
All presented MD values in the main text are means calculated from n=2500 frames per
simulation and presented error values represent the standard deviation of the 2500
frames.
Data availability. The cryo-EM density map and the atomic coordinates of the
econazole-bound full-length TRPV5 channel are deposited into the Electron Microscopy
Data Bank and Protein Data Bank under access codes EMD-7058 and PDB 6B5V. All
other data is available from the corresponding author upon reasonable request. A Life
Science Reporting Summary for this article is available.
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2.6 Figures

Figure 2.1. Econazole bound TRPV5 (TRPV5ECN) structure as determined by cryoEM. (A) Density map of TRPV5ECN at 4.8Å resolution. Each monomer is depicted in a
different color and the density attributed to econazole is shown in yellow. The threshold
of the density map was adjusted so that the putative calcium density is not visible for
better visualization of the pore in this figure. (B) A schematic representation of the
domains present in TRPV5. Dashed lines indicate regions for which a model could not
be build. The lower panels depict the TRPV5ECN model in tetrameric and monomeric
form. (C-D) A density map of a single monomer of TRPV5ECN (pink) with densities
ascribed

to

phosphatidylinositol

(blue)
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and

econazole

(yellow),

respectively.

Figure 2.2. Econazole inhibition of TRPV5. (A) Zoomed in view of the econazole
binding pocket. R-econazole is represented as yellow sticks. Residues that stayed within
4.0Å from at least three of the four econazole molecules during the MD simulations with
either enantiomeric forms are labeled and shown in yellow. (B) A representative two
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electrode voltage clamp (TEVC) trace of wild-type rabbit TRPV5 in Xenopus oocytes
(n=10) at 100 and -100 mV in the presence of 2.2 % DMSO (solvent) and 20 μM
Econazole (ECN), which are indicated by the horizontal lines. TRPV5 currents under
basal conditions are largely blocked by the 1 mM Mg2+ and trace amounts of Ca2+ in the
bath solution. Monovalent currents are initiated by removing Mg2+ and chelating Ca2+
with 1 mM EGTA. (C) A representative two electrode voltage clamp (TEVC) trace of the
F425A mutant rabbit TRPV5 in Xenopus oocytes (n=7) at 100 and -100 mV in the
presence in the presence of 2.2% DMSO (solvent) and 20 μM Econazole (ECN), which
are indicated by the horizontal lines. TRPV5 currents under basal conditions are largely
blocked by the 1 mM Mg2+ and trace amounts of Ca2+ in the bath solution. Monovalent
currents are initiated by removing Mg2+ and chelating Ca2+ with 1 mM EGTA. (D)
Statistical summary (% inhibition) at -100 mV, ***p<0.001, two sample t-test. Error bars
represent ± s.e.m. of the respective n biological replicates. (E-F) The econazole binding
pocket aligned to the TRPV2 (PDB: 5AN8) and TRPV1 (PDB: 3J5R) ligand-binding
pockets. Residues of interest are labeled and shown as sticks.
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Figure 2.3. Ion pore of TRPV5ECN. (A) Dimer cartoon representation and pore profile of
TRPV5ECN generated with HOLE. Constricting residues are labeled and represented as
sticks. (B) Graphic representation of the radius of the TRPV5ECN pore profile. The dotted
line represents the radius of a non-hydrated calcium ion. Residues involved in pore
constriction are labeled. (C) Dimer cartoon representation of the TRPV5ECN pore. Density
attributed to Ca2+ shown in grey mesh. (D) Top down (extracellular) view of the
selectivity filter of the tetrameric TRPV5ECN. The density attributed to Ca2+ is shown in
grey mesh. Dashed lines indicate length from the center of the oxygen atom of Asp542
to the center of the Ca2+ atom. (E) Electrostatic map of the extracellular view of
TRPV5ECN. Blue indicates positive and partial positive regions. Red indicates negative
and partial negative regions. (F) Top down view of the tightest constriction point of the
TRPV5ECN pore at His582. Dashed lines indicate distance between the centers of each
atom.
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Figure 2.4. Pore comparison of select Ca2+ selective ion channels. (A-B) Dimer
ribbon representation and pore profile of TRPV6* (blue, PDB: 5WO7, generously
provided by Dr. Sobolevsky before its release55) and TRPV5ECN (green), respectively.
Pore profiles were generated with HOLE. Constricting residues for each are labeled and
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represented as sticks. Corresponding sequence alignments of rabbit (rb), rat (r) and
human (h) homologues of TRPV5 and TRPV6 as shown in the lower panels.
Constricting residues are colored in red. (C) Graphic representation of the radii of the
TRPV6* (blue), TRPV5ECN (green) and CavAB (pink, PDB: 4MVM) pore profiles. The
dotted line represents the radius of a non-hydrated calcium ion. TRPV5ECN residues
involved in pore constriction are labeled. (D) Dimer ribbon representation and pore
profile of CavAB generated with HOLE. Constricting residues are labeled and
represented as sticks. (E-G) Dimer ribbon representation of the selectivity filters for
TRPV6* (blue), TRPV5ECN (green) and CavAB (pink). Residues expected to be involved
in Ca2+ coordination are labeled and represented as sticks. Calcium ions are shown as
green spheres.
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Figure 2.5. Structural comparison of TRPV5ECN to TRPV6*. (A) Overlaid
transmembrane domains (TMDs) of TRPV5ECN (multicolored) and TRPV6* (blue). The
regions of TRPV5ECN are labeled and colored based on the diagram in Figure 2.1B. The
histidine and tryptophan of interest in each pore are represented as sticks. The
econazole molecule (yellow) from the TRPV5ECN structure is also presented as sticks.
(B) Aligned TRPV5ECN (green) and TRPV6* (blue) dimer pores. Residues of interest are
labeled and shown as sticks. (C) Aligned TRPV5ECN (multicolored) and TRPV6* (blue)
monomers. The regions of TRPV5ECN are labeled and colored based on the diagram in
Figure 2.1B. (D) Superimposed ARDs of TRPV5ECN (orange) and TRPV6* (blue).
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Figure

2.6.

Schematic

representation

of

the

proposed

TRPV5

inhibition

mechanism by econazole. The regions of TRPV5 are colored based on the diagram in
Figure 2.1B. Red arrows denote proposed movement between the uninhibited and
inhibited states of TRPV5.
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Table 2.1. Cryo-EM data collection, refinement and validation.

TRPV5ECN
(EMD-7058, 6B5V)
Data collection and processing
Magnification
Voltage (kV)
Electron exposure (e–/Å2)
Defocus range (μm)
Pixel size (Å)
Symmetry imposed
Initial particle images (no.)
Final particle images (no.)
Map resolution (Å)
FSC threshold
Map resolution range (Å)

45,455
300
44
1.5-4.0
0.55
C4
925,927
50,566
4.8
0.143
3.5-5.5

Refinement
Model resolution cut-off (Å)
FSC threshold
Map sharpening B factor (Å2)
Model composition
Nonhydrogen atoms
Protein residues
Ligands

4.8
0.143
-338
1
2,352
8

R.m.s. deviations
Bond lengths (Å)
Bond angles (°)
Validation
MolProbity score
Clashscore
Poor rotamers (%)
Ramachandran plot
Favored (%)
Allowed (%)
Disallowed (%)

0.03
0.791
2.14
8.79
2.37
94.36
5.64
0.00
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Supplementary Figure 2.1. TRPV5 purification, whole-cell electrophysiology, and
data processing. (A) A size exclusion chromatogram of purified TRPV5. The inset
panel depicts a SDS-PAGE image of purified TRPV5. (B) Whole cell patch clamp
experiments were performed as described in the methods section of Chapter 2 (2.5
Methods) in HEK293 cells transfected with rbTRPV5 using a ramp protocol from -100 to
100 mV; currents are plotted at -100 and 100 mV, zero current is indicated by the
dashed line. Representative trace, monovalent currents were initiated by removal of
extracellular Ca2+ and Mg2+ and the application of 0.33 % DMSO and 3 μM econazole is
indicted by the horizontal lines. (C) Concentration response curve for econazole. Error
bars represent ± s.e.m. of the respective n biological replicates. (D) The first panel is a
representative micrograph of TRPV5 incubated with econazole frozen in vitreous ice.
Scale bar = 25nm. The second panel depicts representative 2D class averages used
when reconstructing the TRPV5ECN structure. (E) The workflow used to reconstruct
TRPV5ECN to 4.8Å. Boxes around a 3D class indicate that that class was taken for further
processing.
49

Supplementary Figure 2.2. Resolution data for TRPV5ECN refinement. (A) FSC
curves for masked and unmasked reconstructions. The dashed line represents an FSC
of 0.143. (B) The angular distribution of 2D views for the final particles used for the
reconstruction. High numbers of particles are represented as taller red cylinders while
views with a low number of particles are shown as shorter blue cylinders. The final
density map of TRPV5ECN is shown in grey. (C) Multiple views of the local resolution map
of TRPV5ECN. Local resolution was determined using ResMap software.
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Supplementary Figure 2.3. TRPV5 model validation. (A) Various helices of the
TRPV5ECN model (cartoon) overlaid with the final TRPV5ECN density map (mesh). Select
residues are shown as sticks to illustrate the accuracy of the model. All helices shown
are within the 3.5-4.0Å region of the structure. (B) Other domains of the TRPV5ECN
model (cartoon) overlaid with the final TRPV5ECN density map (mesh). The different
regions of the TRPV5ECN model are colored based on the diagram in Figure 2.1B.
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Supplementary Figure 2.4. Binding sites among TRPV subfamily members. (A)
Density maps of econazole (ECN) bound rabbit TRPV5, capsazepine (CPZ) bound rat
TRPV1 solved in nanodiscs and ligand free rat TRPV1 solved in nanodiscs. Densities
attributed to lipids in each structure are colored in blue. The lipid to which each density
was ascribed is listed below each structure. (B) Density maps of econazole (ECN)
bound rabbit TRPV5, capsazepine (CPZ) bound rat TRPV1 solved in nanodiscs. ECN
densities are shown in yellow. Capsazepine densities are shown in orange.
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Supplementary Figure 2.5. Econazole-binding pocket. (A) Molecular structure of
econazole. The asterisk indicates the location of chiral center. (B) Zoomed in view of the
econazole binding pocket manually fitted with R-econazole (C) Zoomed in view of the
econazole binding pocket manually fitted with S-econazole (D-E) An electrostatic map of
TRPV5ECN was calculated via APBS software. The zoomed views depict the econazole
binding pocket with R-econazole or S-econazole shown in yellow.
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Supplementary Figure 2.6. Econazole effect on mutant TRPV5. Two electrode
voltage clamp (TEVC) experiments were performed similar to that described in Figure
2.2 on Xenopus laevis oocytes injected with cRNA encoding the wild type or various
mutants of rabbit TRPV5. (A-E) Representative traces for for WT and various TRPV5
mutants, currents are shown at -100 and +100 mV, zero current is indicated by the
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dashed line, the applications of 2.2 % DMSO (solvent) and 20 μM econazole (ECN) are
indicated by the horizontal lines. (F). Summary of the effects of 20 μM econazole and 2.2
% DMSO. *** p<0.001 indicates a difference between econazole inhibition in WT (first
black column). ##p<0.01, ###p<0.001 indicates a difference from the effect of DMSO on
WT channels (first grey column); one way analysis of variance with Bonferroni post hoc
comparison. Error bars represent ± s.e.m. of the respective n biological replicates.
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Supplementary Figure 2.7. Comparison of ligand binding pockets within the TRPV
subfamily. (A) The transmembrane domain (TMD) of TRPV5ECN. Bound econazole
(ECN) is represented as yellow sticks. The regions of TRPV5ECN are colored based on
the diagram in Figure 2.1B. (B) The TMD of rat TRPV1 solved in nanodiscs in the
absence of ligand (purple, PDB: 5IRZ). Bound phosphatidylinositol, a lipid cofactor of
TRPV1, is shown in grey sticks. (C) The TMD of rat TRPV1 solved in nanodiscs in the
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presence of the inhibitor capsazepine (orange, PDB: 5IS0). The capsazepine molecule
(CPZ) is shown in grey. (D) The TMD of rat TRPV1 solved in nanodiscs in the presence
of the potent agonists, resiniferatoxin (RTX) and double-knot toxin (DkTx) is shown in
red (PDB: 5IRX). The pocket depicted coordinates RTX (grey).
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Supplementary Figure 2.8. Econazole flexibility during MD production run. (A)
Time evolution of the RMSD of R-econazole (labeled ECN_1 to ECN_4) with respect to
the initial manual docking into the assigned electron density within the four monomers of
TRPV5 (monomers A to D, respectively) during the 25 ns production run. (B) Time
evolution of the RMSD of S-econazole (labeled ECN_1 to ECN_4) with respect to the
initial manual docking into the assigned electron density within the four monomers of
TRPV5 (monomers A to D, respectively) during the 25 ns production run.
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Supplementary Figure 2.9. TRPV5 stability during MD production run. Time
evolution of (A) RMSD of Cα-atoms of TM helices S1 to S6 (blue) and all Cα atoms of
the TRPV5 tetramer (red) bound to R-econazole, and (B) Cα RMSF for each monomer
during the 25 ns production run of the TRPV5 complex bound to R-econazole. Panels C
and D show the time evolution of RMSD and RMSF values for the TRPV5 complex
bound to S-econazole.
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Supplementary Figure 2.10. Flexibility of econazole molecules during MD
production run. Binding modes of four R-econazole molecules (grey carbons; labeled
ECN_1 to ECN_4 in panels (A-D) sampled during the 25 ns production run and
compared to the initial manually docked pose of R-econazole (yellow carbons) into the
assigned electron density. Each panel A-D shows five conformations of R-econazole
within the four monomers of TRPV5 (monomers A to D colored blue, red, green, and
dark grey, respectively) at simulation times 5 ns, 10 ns, 15 ns, 20 ns, and 25 ns.
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Supplementary Table 2.1. Distances between econazole and the cryo-EM-inferred
binding pocket residues of TRPV5. Those that remained within 4.0 Å from at least
three of the four econazole molecules in either enantiomeric form during MD simulations
are in bold. Distances reported are between heavy atoms of econazole and side chain
heavy atoms of TRV5 residues. Error bars correspond to standard deviation of distance
values sampled during simulation (n=2500).

Residues
F425
I428
F456
L460
C463
M466
I482
I486
I564
I565

Econazole S-enantiomer
Minimum Average minimum distance
Distance
(Å) during MD
(Å) in
docked
structure
ECN1 ECN2 ECN3 ECN4
3.4
4.4
3.8
3.6
3.7
±
±
±
±
0.9
0.3
0.3
0.3
3.4
3.9
3.7
3.7
3.9
±
±
±
±
0.4
0.2
0.2
0.3
7.7
6.7
4.3
7.2
4.0
±
±
±
±
2.0
0.8
1.0
0.4
3.5
6.0
4.0
4.2
3.9
±
±
±
±
1.5
0.5
0.5
0.4
3.9
4.6
3.8
3.7
4.1
±
±
±
±
0.9
0.3
0.3
0.4
4.0
5.2
4.3
4.8
3.7
±
±
±
±
1.5
0.7
0.9
0.3
3.8
4.7
3.8
4.2
4.1
±
±
±
±
1.0
0.3
0.5
0.4
4.0
3.7
3.7
3.8
3.8
±
±
±
±
0.2
0.3
0.2
0.3
4.0
5.5
8.7
8.6
7.8
±
±
±
±
1.6
0.7
0.6
0.6
3.6
4.0
3.8
4.0
3.8
±
±
±
±
0.6
0.4
0.4
0.3

Residues
F425
I428
F456
L460
C463
M466
I482
I486
I564
I565
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Econazole R-enantiomer
Minimum
Average minimum distance
Distance
(Å) during MD
(Å) in
docked
structure
ECN1 ECN2 ECN3 ECN4
2.8
5.8
3.9
4.9
4.0
±
±
±
±
1.4
0.4
0.7
0.5
4.2
3.9
3.9
3.6
3.7
±
±
±
±
0.3
0.3
0.2
0.3
2.4
4.2
4.2
5.2
3.9
±
±
±
±
0.6
0.7
1.7
0.4
2.1
3.8
3.8
3.8
3.7
±
±
±
±
0.5
0.3
0.3
0.2
4.4
3.8
4.0
3.8
3.7
±
±
±
±
0.3
0.4
0.3
0.3
5.0
5.2
4.0
5.2
4.7
±
±
±
±
1.5
0.5
1.1
0.8
3.8
5.3
7.1
4.0
5.0
±
±
±
±
1.5
1.2
0.5
1.0
5.8
3.9
4.6
3.9
3.7
±
±
±
±
0.4
0.6
0.3
0.2
5.7
6.3
11.0
5.4
5.8
±
±
±
±
1.6
0.7
1.9
1.3
3.9
3.8
6.9
4.0
3.8
±
±
±
±
0.3
0.6
0.5
0.3
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3.1 Abstract
TRPV5 is a transient receptor potential channel involved in calcium reabsorption.
Here we investigate the interaction of two endogenous modulators with TRPV5. Both
phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) and calmodulin (CaM) have been
shown to directly bind to TRPV5 and activate or inactivate the channel, respectively.
Using cryo-electron microscopy (cryo-EM), we determined TRPV5 structures in the
presence of dioctanoyl PI(4,5)P2 and CaM. The PI(4,5)P2 structure revealed a novel
binding site between the N-linker, S4-S5 linker and S6 helix of TRPV5. These
interactions with PI(4,5)P2 induce conformational rearrangements in the lower gate,
opening the channel. The CaM structure revealed two TRPV5 C-terminal peptides
anchoring a single CaM molecule and that calcium inhibition is mediated through a
cation-π interaction between Lys116 on the C-lobe of calcium-activated CaM and Trp583
at the intracellular gate of TRPV5. Overall, this investigation provides insight into the
endogenous modulation of TRPV5, which has the potential to guide drug discovery.
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3.2 Introduction
The calcium ion is vital for an array of cellular functions, and in the human body
the kidneys regulate calcium homeostasis by filtration and reabsorption92. Around 99%
of calcium is reabsorbed by the kidney tubules92, with ~15% of that reabsorption
occurring via transient receptor potential vanilloid 5 (TRPV5) channels in the distal
convoluted tubule and collecting tubule. TRPV5 is specialized for this task and is only
expressed in the apical membrane of kidney epithelial cells in the distal convoluted
tubule and collecting tubule

13,44

. When open, TRPV5 allows calcium in the urine to flow

along a concentration gradient through the channel pore into the cell. This gradient is
maintained by the calcium sequestering protein calbindin, which delivers calcium to
active transport proteins at the basolateral membrane of the epithelium, which then
export the ions into the blood stream13,44. Though this mechanism of calcium
reabsorption is responsible for only ~15% of total calcium reabsorbed in the kidney,
TRPV5 activity is critical for the homeostatic balance of calcium13,44. This is exemplified
by TRPV5 knock out mice, which have been reported to have systemic calcium
imbalance in the form of hypercalciuria and bone mineral loss13,44. In humans, single
nucleotide polymorphisms in TRPV5 in African-American populations result in a
significant increase in calcium reabsorption that is correlated with a lower risk of
nephrolithiasis13,44. Together, these observations suggest that TRPV5 could be a
potential drug target for human disorders involving altered calcium homeostasis.
TRPV5 is a calcium selective channel that displays constitutive activity in the
presence of basal levels of the membrane phospholipid phosphatidylinositol 4,5bisphosphate (PI(4,5)P2)13. The TRPV5 channel is tetrameric and consists of classic
TRPV family features, including six transmembrane helices (S1-S6), N-terminal ankyrin
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repeats (ARD), and the TRP domain27 (Figure 3.1A).

TRPV6 is a closely related

epithelial Ca2+ channel that shows a high level of sequence homology with TRPV544;
these two channels have a much lower level of sequence homology with other members
of the TRPV subfamily. The regulation and biophysical properties of TRPV5 and TRPV6
are similar, and they are functionally quite different from the rest of the TRPV
subfamily44. PI(4,5)P2 is found in the inner leaflet of the plasma membrane and it has
been shown to be essential for the activity of both TRPV593,94 and TRPV695. For TRPV6,
the activating effect of PI(4,5)P2 was demonstrated in planar lipid bilayers, providing
definitive evidence for direct effect on the channel96. However, the molecular details of
the PI(4,5)P2 interaction with TRPV5 and TRPV6 are essentially unknown.
To prevent excess flow of calcium ions into the cell, both TRPV5 and TRPV6 have
been shown to rapidly inactivate through a calcium-dependent mechanism97. Calmodulin
(CaM), a calcium sensing protein, has been shown to be involved in this inactivation by
directly interacting with the last thirty amino acids of the TRPV5 C-terminus98. While the
role of the distal C-terminal binding site is well established in CaM-mediated inactivation
of TRPV598 and the closely related TRPV699-101, the binding stoichiometry and the
conformational changes that take place as a consequence of the binding of CaM to the
channel have been unclear44. The absence of this information prevents us from further
understanding TRPV5 function and regulation in the kidney.
In this study, we used cryo-electron microscopy (cryo-EM) to uncover the
molecular mechanisms of TRPV5 gating via endogenous modulators. Investigating
TRPV5 modulation with cryo-EM permitted us to gain insight regarding TRPV5 gating
and potentially form the basis for rational drug design for the treatment and prevention of
hypercalciuria and nephrolithiasis in future studies.
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3.3 Results
Structures of TRPV5 in the lipid-bound and in the PI(4,5)P2-bound states
TRPV5 is part of the tightly regulated system of calcium homeostasis in the
human body13. Two endogenous mechanisms of regulation, binding of PI(4,5)P2 or CaM
to TRPV5, result in activation or inactivation of the channel101, respectively. To
understand these mechanisms of modulation, first we used cryo-EM to determine the
structure of detergent solubilized full-length rabbit TRPV5 in the presence of the 200 μM
dioctanoyl (diC8) PI(4,5)P2, a soluble form of PI(4,5)P2. This concentration is ~3 times
the half-maximal response (EC50) of diC8 PI(4,5)P2 for TRPV6, and TRPV5 has a slightly
higher apparent affinity for diC8 PI(4,5)P271, thus this concentration was expected to
result in near saturation of TRPV5 with diC8 PI(4,5)P2. During the cryo-EM structure
determination process, one stable class emerged and was refined to an overall
resolution of 3.9 Å (Figure 3.1B, Table 3.1, Supplementary Figure 3.1, Supplementary
Figure 3.2). The vast majority of this TRPV5 cryo-EM map is at high resolution (3-3.5 Å)
as side chains are clearly visible in the transmembrane region of the channel
(Supplementary Figure 3.1, Supplementary Figure 3.3). This allowed for accurate model
building in both the transmembrane domain (TMD) and the ankyrin repeat domain (ARD)
(Figure 3.1C, Supplementary Figure 3.3). Highly flexible areas such as the very distal Cand N-termini were unable to be resolved. Interestingly, five non-protein densities per
monomer were identified in this cryo-EM map (Figure 3.1B). None of these could be
identified as diC8 PI(4,5)P2, and were attributed to annular lipids that had high enough
affinity for TRPV5 to be co-purified with the protein.
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Similarly shaped non-protein

densities were also assigned as lipids in a recently reported human TRPV6 cryo-EM
structure102. Therefore, we will refer to this channel reconstruction as lipid-bound TRPV5.
The lipid-bound TRPV5 pore contains three residues that are involved in pore
constriction: Asp542, Ile575 and Trp583 (Figure 3.1D). Unlike the previously published
structure of TRPV527, there is clear density in the lipid-bound TRPV5 map indicating that
the four Asp542 that constitute the highly specific Ca2+ selectivity filter are pointing
directly into the pore in a similar fashion to the rat TRPV6 crystal structures54,55. The
lipid-bound TRPV5 lower gate appears to consist of Ile575 and Trp583 (Figure 3.1D-E).
These residues do not constrict the pore to the point of blocking ion translocation,
indicating that the lower gate is open (Figure 3.1E), as seen in the human TRPV6 cryoEM structure102. This suggests that the pore of the lipid-bound TRPV5 structure may be
in a closed pre-open conformation.
Based on these findings, we decided to increase diC8 PI(4,5)P2 concentration to
400 μM and use nanodiscs to capture TRPV5 in the PI(4,5)P2-bound state. During the
cryo-EM structure determination process we noted that even before masking and 3D
classification in RELION60,103 the initial 3D reconstruction contained a non-protein density
that resembled diC8 PI(4,5)P2 in both size and shape (Figure 3.2A, Supplementary
Figure 3.4). Next, we used particle subtraction and 3D classification that was focused on
the diC8 PI(4,5)P2 binding site using a mask which included the entire TRP domain helix,
the base of the S6 helix, and the head group of the diC8 PI(4,5)P2 (Supplementary Figure
3.4). This classification yielded three classes with good features: one without diC8
PI(4,5)P2 and two with diC8 PI(4,5)P2 (Supplementary Figure 3.4). The class without diC8
PI(4,5)P2 yielded a TRPV5 structure at 4.4Å , which clearly resembled the lipid-bound
TRPV5 in detergent (Supplementary Figure 3.5). Due to high similarity between the
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detergent and nanodisc lipid-bound TRPV5 structures (Supplementary Figure 3.5), we
will only describe the lipid-bound TRPV5 in detergent as it was determined at a higher
resolution (Supplementary Figure 3.1, Supplementary Figure 3.3, Supplementary Figure
3.5). The two classes with diC8 PI(4,5)P2 density, after additional classification and
refinement, produced a single TRPV5 structure in a diC8 PI(4,5)P2-bound state at 4.0 Å
(Figure 3.2B, Table 3.1, Supplementary Figure 3.6, Supplementary Figure 3.7). All
structures identified in nanodiscs revealed non-protein densities in similar positions to
those attributed to annular lipids in the lipid-bound TRPV5 structure in detergent (Figure
3.1B, Figure 3.2A-B, Supplementary Figure 3.5).
The PI(4,5)P2 binding site in the TRPV5 channel is located between the N-linker
(Arg302, Arg305), S4-S5 linker (Lys484) and the S6 helix (Arg584) of the channel
(Figure 3.2C). These results show an excellent correlation with predictions by earlier
molecular dynamics (MD) simulations performed on the homologous TRPV6 channel
(Figure 3.2D, Supplementary Figure 3.8). These simulations predicted that residues
Arg302, Arg305, and Lys484 are involved in the TRPV6 interaction with PI(4,5)P2 (Figure
3.2D, Supplementary Figure 3.8). Moreover, when these predicted PI(4,5)P2 interacting
TRPV6 residues (Arg302, Arg305, Lys484) were mutated to glutamine, the channel had
increased sensitivity to depletion of PI(4,5)P2 with high concentrations of wortmannin,
which inhibits PI4-kinases (Figure 3.2E). This result indicates reduced apparent affinity
for PI(4,5)P2, which is expected if a PI(4,5)P2 interacting residue is mutated104. The
current amplitudes of the Arg302Gln and Lys484Gln mutants were also significantly
lower than wild type TRPV6 (Supplementary Figure 3.9), which is also consistent with
decreased apparent affinity of the channel for PI(4,5)P2. The Arg305 residue showed a
less clear contact with PI(4,5)P2 compared to Arg302 and Lys484, interacting with only
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three out of four subunits in MD simulations (Supplementary Figure 3.8). Accordingly,
this mutant showed a less pronounced trend to be inhibited more by wortmannin and
had a smaller amplitude, but these effects did not reach statistical significance from wild
type (Figure 3.2E, Supplementary Figure 3.9). When we mutated residues Arg302 and
Lys484 to glutamine in TRPV5 and performed analogous experiments, we observed that
the TRPV5 channel also had significantly increased sensitivity to the depletion of
PI(4,5)P2 with high concentrations of wortmannin, suggesting that both TRPV5 and
TRPV6 share a similar PI(4,5)P2 binding site (Figure 3.2F). Unlike for TRPV6, current
amplitudes for these mutants were not statistically significantly different from wild type
TRPV5 (Supplementary Figure 3.9).
Based on the structure of PI(4,5)P2 -bound TRPV5 compared to the lipid-bound
TRPV5, the binding of diC8 PI(4,5)P2 to TRPV5 appears to induce conformational
changes related to channel activity. The pore of the channel widened, which could allow
for the flow of hydrated Ca2+ ions (Figure 3.3A-D). Specifically, the Asp542 residues,
which line the selectivity filter of the channel and coordinate Ca2+ ions, point upwards
in the extracellular vestibule of the channel instead of towards the ion conduction
pathway as seen in the lipid-bound structure (Figure 3.3D). The distance between the
center of the carboxylate oxygen atoms of the Asp542 residues in this structure is ~3
Å, which would allow for partially hydrated Ca 2+ ion to flow though the pore of the
channel (Figure 3.3C-D). The lower gate of the channel is also wide open (~12 Å
compared to ~8 Å in the lipid-bound state) due to the movement of the S6 helix and
Trp583 upon binding of diC8 PI(4,5)P2 (Figure 3.3E), which would facilitate the
movement of partially hydrated Ca2+ ions through the pore (Figure 3.3C). Additionally,
diC8 PI(4,5)P2 binding caused global conformational changes in the S6 and TRP
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helices as well as the S4-S5 linker when compared to the lipid-bound structure (Figure
3.3F).
Comparison between the diC8 PI(4,5)P2-bound and lipid-bound TRPV5 structures
revealed details of the conformational changes induced by PI(4,5)P2 binding (Figure
3.4). The inositol ring of the diC8 PI(4,5)P2 head group is positioned close to the lower
gate of the channel, where phosphate groups at position four and five can interact
directly with Arg584 and Arg302, respectively (Figure 3.4A and 3.4C). Specifically, the
phosphate group at the position four forms a salt bridge with the Arg584 on the S6 helix.
This interaction is facilitated by the rotation of the Arg584 towards the PI(4,5)P2, which
pulls the S6 helix away from the center of the pore, starting at the π-helix (Figure 3.3B),
and causes an outward shift of the S4-S5 linker (Figure 3.3F). The rotation of Arg584
also induces the lengthening of the S6 helix and shortens the TRP helix (Figure 3.3F,
Figure 3.4A-B). In the lipid-bound TRPV5 structure, the transition between the S6 helix
and the TRP helix occurs between Arg584 and Val585, while in the diC8 PI(4,5)P2-bound
TRPV5 structure this transition occurs between residues Gln587 and Glu588. The
extension and rotation of the S6 helix pulls Trp583 out of the pore and stabilizes its
position through an interaction with Gln587, thus opening the lower gate. The shortening
of the TRP helix causes Glu588 to pull away from Arg302, allowing Arg302 to interact
with the phosphate group at position five of the diC8 PI(4,5)P2 head group (Figure 3.4CD). Additionally, Lys484 interacts with the diC8 PI(4,5)P2 inositol ring, which further
electrostatically stabilizes the position of diC8 PI(4,5)P2 in its binding pocket (Figure 3.4CD).
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TRPV5 inhibition by calmodulin
In order to investigate the mechanism of TRPV5 inactivation by CaM, we
incubated detergent solubilized full-length rabbit TRPV5 with calcium-activated rat CaM
in a 1:20 molar ratio in the presence of 10 mM CaCl2. The stoichiometry of TRPV5 to
CaM has been speculated to be between one and four molecules of CaM per
tetramer23,43,44,94,97,105 and the affinity between CaM and the TRPV5 C-terminus is
estimated at ~0.3 µM106, therefore the high molar ratio was used to ensure TRPV5
saturation with CaM. This sample yielded a cryo-EM map at 4.4 Å without applied
symmetry (Figure 3.5A, Table 3.1, Supplementary Figure 3.10, Supplementary Figure
3.11, Supplementary Figure 3.12). In this structure, a single CaM molecule is bound to
the intracellular section of TRPV5 at the base of the pore (Figure 3.5A). Both lobes of
CaM are resolved and each bound to different sections of the TRPV5 C-terminus (Figure
3.5A-B, Supplementary Figure 3.12). Despite the interaction with CaM, the CaM-bound
conformation of TRPV5 is almost identical to the lipid-bound conformation of TRPV5,
with an RMSD of ~0.6A overall and a very similar pore profile (Figure 3.5C-D).
Additionally, annular lipids were also identified in the CaM-bound TRPV5 structure in
similar positions to those in the lipid-bound TRPV5 structure in detergent (Figure 3.1B,
Figure 3.5A).
CaM is bound with the C-lobe at the base of the pore and the N-lobe resting
against the ankyrin repeats of two adjacent TRPV5 monomers (Figure 3.5A-B).

A

portion of the CaM N-lobe (Gly41-Ile64) and the linker between the CaM two lobes
(Lys78-Ser82) are visible only as broken density and were excluded from the model
(Figure 3.6A). A peptide from the C-terminus of TRPV5 (His699-Thr709) is bound to the
CaM C-lobe, with TRPV5 Trp702 making critical contacts with the CaM binding pocket,
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as previously reported23 (Figure 3.6A and 3.6C). This peptide was arbitrarily assigned to
TRPV5 chain A in the model, but no connections could be seen between the density for
this peptide and any TRPV5 monomer. An extension of the TRPV5 chain A C-terminus
(Asn640-Lys652) forms a helix and is bound to the hydrophobic binding pocket of the
CaM N-lobe (Figure 3.6B).

This interaction is mediated by numerous hydrophobic

contacts: Val644, Leu645, Val648, and Phe651 on the TRPV5 side and Phe20, Leu33,
Val36, and Leu64 on the CaM side (Figure 3.6A and 3.6D). A loop of the CaM C-lobe
(Gly114-Thr118) crosses over the bottom of the TRPV5 pore, placing Lys116 directly
into the pore. The ε-amino group of Lys116 sits in between the four Trp583 residues of
the lower gate, forming a cation-π interaction and thereby blocking the flow of ions
through the pore (Figure 3.6E). To test the functional importance of Trp583 in TRPV5
inhibition by CaM, we performed excised inside out patch clamp experiments. Wild type
TRPV5 currents were robustly inhibited by Ca2+-CaM (0.2 μM CaM, 3 μM free Ca2+)
applied to the inner leaflet of the patch membrane (Figure 3.6F and 3.6H), as previously
reported for TRPV6101. On the other hand, the mutation of Trp583 to Leu in TRPV5 was
essentially not inhibited by Ca2+-CaM (Figure 3.6G and 3.6H). Thus, this cation-π
interaction appears to be critical for CaM-induced inhibition of TRPV5 (Figure 3.6F-H).
3.4 Conclusions
Here we have presented three structures of TRPV5, one in the presence of
endogenous lipids that are likely to be involved in maintaining the structure of TRPV5,
one bound to its endogenous activator, PI(4,5)P2 and one bound to its endogenous
inhibitor, CaM. The high-resolution, lipid-bound TRPV5 has allowed for more accurate
model building of TRPV5 than available previously27. This structure also identified the
binding pockets for several high affinity lipids which were consistently seen in all TRPV5
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structures presented here. These binding pockets have the potential to be drugable
areas of the TRPV5 channel as they are both membrane and solvent accessible and are
in contact with regions that have been reported to be able to transmit conformational
rearrangements to the pore in other TRPV family channels27,63,102.
PI(4,5)P2 is a conserved positive regulator of most TRP channels104. The TRPV5bound PI(4,5)P2 structure revealed directly for the first time how a TRP channel is
opened by this important endogenous lipid at the molecular level. Similar binding sites
for PI(4,5)P2 have been theoretically predicted for TRPV1107 and TRPV671 channels
using computational modeling and experimental approaches, suggesting that the S4-S5
linker plays an essential role in this interaction. Our cryo-EM structure directly
demonstrates an interaction between PI(4,5)P2 and TRPV5 through the N-linker, the S4S5 linker and the S6 helix of each TRPV monomer (Figure 3.2). Comparison between
the PI(4,5)P2 -bound and lipid-bound TRPV5 structures revealed that binding of PI(4,5)P2
near to the lower gate of the TRPV5 channel induces conformational changes in the
pore, which allows for the flow of Ca2+ ions (Figure 3.3, Figure 3.7).
The CaM-bound structure has provided the first structural insight into how
TRPV5 ion flow is inhibited by CaM. It is clear that the binding of a single CaM molecule
completely obstructs the intracellular side of the pore, effectively blocking ion permeation
(Figure 3.7). This study also showed that while CaM binds to the predicted areas in the
C-terminus of TRPV5, it also directly interacts with the C-terminus at a novel binding site
(Figure 3.6). Taken together, the lipid- and CaM-bound TRPV5 structures provide
additional evidence for the static nature of some TRPV subfamily channels63,102. The
minimal movement (RMSD ~0.6Å) between the two structures implies that large
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conformational changes in the upper and lower gates of TRPV5 may not be necessary
for effective endogenous inhibition.
It has previously been shown that the N- and C-lobes of CaM have different
affinities for calcium ions, with the C-lobe having a 6-fold higher affinity for calcium ions
than the N-lobe108. Other groups have proposed that this allows the CaM C-lobe to be
constantly bound to the distal C-terminus of TRPV5 at normal cellular calcium levels,
keeping a constant supply of CaM near the pore23,109. In this model, the N-lobe only
binds to the C-terminus of TRPV5 when calcium is high and the pore needs to be
closed, and the second CaM binding event may stabilize the position of CaM at the base
of the pore and lead to the occlusion of the channel23,109. The new CaM N-lobe binding
site at TRPV5 residues Asn640-Lys652 could compliment the previous model, by
potentially “reeling in” CaM when calcium levels are high and bringing the CaM C-lobe
into close proximity with the base of the pore.
Overall, our structural studies have provided novel molecular insights into the
endogenous modulation of TRPV5 that could guide novel therapeutics design for a
variety of calcium dependent kidney diseases.
3.5 Methods
Expression and purification of TRPV5
TRPV5 was expressed as reported previously27. In short, full-length rabbit
TRPV5 was expressed with a 1D4 affinity tag in S. cerevisiae59,110. The membranes
were lysed and harvested using a M-110Y microfluidizer and ultracentrifugation. TRPV5
was purified using previously published methods27. Briefly, membranes containing
TRPV5 were solubilized in Buffer A (150mM NaCl, 2mM TCEP, 1mM PMSF, 20 mM
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HEPES pH8, 10% glycerol and 0.87 mM LMNG). Non-soluble material was removed via
ultracentrifugation. Detergent solubilized TRPV5 was then purified using CnBr-activated
Sepharose 4B beads conjugated to 1D4 specific antibodies. The beads were washed
with Buffer B (150mM NaCl, 2mM TCEP, 20 mM HEPES pH8, and 0.064 mM DMNG)
and TRPV5 was eluted using Buffer B with the addition of 3 mg/mL 1D4 peptide.
The sample involved in the reconstruction of lipid-bound TRPV5 in detergent was
then subjected to size exclusion chromatography (Superose 6, GE Healthcare) in Buffer
B. This sample was concentrated to ~2.5mg/mL and incubated with soluble diC8
PI(4,5)P2 at a final concentration of 200µM for 30 minutes prior to vitrification.
For the sample that was reconstituted into nanodiscs, after elution from the
Sepharose beads TRPV5 was incubated with MSP2N2 and soy polar lipid extract
(Avanti Polar Lipids, Inc.) in a molar ratio of 1:1:200 (TRPV5:MSP2N2:Soy Polar Lipids)
for 30 min. MSP2N2 (Addgene) was expressed and purified as previously published111,
except the protein was induced at 28°C instead of 37°C. Soy polar lipids were dried
under nitrogen flow for 3 hrs prior to reconstitution and dried lipids were resuspended
with a 1:200 molar ratio of lipids to DMNG before being added to the protein mixture.
Bio-Beads (Bio-Rad, Bio-Beads SM-2 Absorbent Media) were added to the TRPV5,
MSP, lipid mixture for 1 hr. Fresh Bio-Beads were then added and allowed to incubate
overnight. The reconstituted nanodiscs were further purified using size exclusion
chromatography (Superose 6, GE Healthcare) in Buffer C (150mM NaCl, 2mM TCEP
and 20 mM HEPES pH 8). This sample was concentrated to ~2.8mg/mL and incubated
with soluble diC8 PI(4,5)P2 at a final concentration of 400µM for 30 minutes prior to
vitrification.
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The TRPV5 sample used for the reconstruction of CaM-bound TRPV5 was
incubated for 1 hr with 10mM CaCl2 and purified rat CaM (a gift from the Dr. Zhang lab at
Thomas Jefferson University, purified as previously published112) at a molar ratio of 1:20
(TRPV5 tetramer:CaM) after elution from the Sepharose beads. The TRPV5-CaM
mixture was then further purified using size exclusion chromatography (Superose 6, GE
Healthcare) in Buffer B. No chelating agents were added to Buffer B; thus, trace
amounts of calcium are present in the final sample. The peak containing CaM-bound
TRPV5 was concentrated to ~3mg/mL.
Cryo-EM data acquisition
For all samples, fluorinated Fos-Choline-8 was added to the concentrated protein
to a final concentration of 3mM immediately prior to vitrification. Samples were double
blotted on 200 mesh Quantifoil 1.2/1.3 grids (Quantifoil Micro Tools) with 3.5µL per blot
and plunge frozen in liquid ethane using a Vitrobot (Thermo Fisher Scientific). Grids
containing TRPV5 and diC8 PI(4,5)P2 in detergent as well as grids with CaM-bound
TRPV5 were imaged with a 300kV Titan Krios microscope equipped with a Gatan K2
Summit direct detector camera. Super resolution movies (50 frames) were captured
for 10 sec each with one frame collected every 0.2 sec. The resultant pixel size and
dose rate were 0.55 Å/pix and ~8 electrons/pix/sec, respectively. Images were
collected in a defocus range between 1.0-2.5µm under focus in an automated fashion
using Leginon software72.
Grids containing TRPV5 and diC 8 PI(4,5)P2 in nanodiscs were also imaged with
a 300kV Titan Krios microscope equipped with a Gatan K2 Summit direct detector
camera. Super resolution movies (40 frames) were captured with an 8 sec exposure
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time in super resolution mode resulting in a pixel size and dose rate of 0.532 Å/pix
and ~6 electrons/pix/sec, respectively. Images were collected in a defocus range
between 1.25-2.5µm under focus.
Image processing
Lipid-bound TRPV5 in detergent
MotionCor273 was used to correct for beam induced motion and to bin the
images to a final pixel size of 1.1Å, producing both summed and dose weighted
micrographs. CTF estimation of the summed micrographs was preformed using Gctf74.
All other image processing was performed using RELION on the dose weighted
micrographs unless otherwise mentioned60,103. Approximately 2,500 particles were
picked manually from 3,889 micrographs and sorted into 2D classes. The best classes
were used as templates for autopicking. After autopicking, 2D classification was used to
remove false positives and suboptimal particles. The remaining ~241,000 particles were
reconstructed into a single electron density map with C4 symmetry using the 3D autorefine option in RELION followed by 3D classification into 8 classes without assigning
angles to the particles. The initial model used for 3D refinement and classification was
produced by applying a low-pass filter of 60Å to the previously published TRPV5 cryoEM structure27. The best class by manual inspection underwent multiple rounds of 3D
refinement followed by 3D classification until the best ~26,000 particles were able to be
reconstructed into 4.4Å map. The mask used for this reconstruction was created from
the original 3D auto-refinement of ~241,000 particles adjusted to a threshold of 0.005,
lowpass filtered to 15Å and a soft edge of 5 pixels was applied. A separate dataset
collected under the same conditions on grids prepared at the same time as the sample
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above produced 3,062 additional micrographs. The same methods as above were
implemented and resulted in a map containing ~19,000 particles that was reconstructed
to 4.2Å. These particles were then combined using the JoinStar command in Relion to
produce a particle set of ~45,000 particles that were refined to 4.1Å in RELION
(Supplementary Figure 3.2). A b-factor of -174 was then applied to the unsharpened
map using Bfactor software and the final resolution of 3.9Å was determined using
rmeasure software113,114. Local resolutions were estimated using the RESMAP
software75.
PI(4,5)P2 bound TRPV5 in nanodiscs
MotionCor273 was used to correct for beam induced motion and to bin the
images to a final pixel size of 1.1Å, producing both summed and dose weighted
micrographs. CTF estimation of the summed micrographs was preformed using Gctf74.
All other image processing was performed using RELION on the dose weighted
micrographs unless otherwise mentioned60,103. To create templates for autopicking,
2,112 particles were manually picked from 1,575 micrographs and sorted into 21
classes. The best classes were used to autopick 493,047 particles which were then
subjected to 2D classification into 200 classes to remove false positives and suboptimal
particles. The best classes contained 121,980 particles, which were refined to 4.4Å
using 3D AutoRefine with C4 symmetry in the absence of a mask using the same initial
model as in the lipid-bound structure. A mask was created of this structure by adjusting
the threshold to 0.005, lowpass filtering to 15Å and applying a soft edge of 5 pixels. The
4.4Å structure was postprocessed using the above mask to produce the Initial 3D
Reconstruction at 4.3Å (Supplementary Figure 3.4). A cylinder with a radius of 40Å and
height of 15Å was created in Chimera, centered on the pore at the height of the TRP
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helices. This cylinder was used to make a mask at a threshold of 0.5, an extended edge
of 2 pixels, and a soft edge of 5 pixels. This mask was then used for particle subtraction,
where everything outside of this mask was subtracted, as previously described37. The
subtracted particles were then sorted by 3D classification into 5 classes without
assigning angles, yielding three high resolution classes. Two of these classes had
density for PI(4,5)P2 (total of ~72,000 particles) and one had no PI(4,5)P2 density
(~30,000 particles).

We swapped both sets of subtracted particles back to the

unsubtracted particles and refined both sets using the mask previously used to refine the
~121,000 particle map.

The ~30,000 particles for the class without PI(4,5)P2 were

refined to 4.5Å in RELION. Postprocessing was run on this data in RELION using the
same mask as previously with an applied b factor of -200, leading to a final resolution of
4.4Å. The ~72,000 particles were then sorted again by 3D classification into 3 classes
without assigning angles. The best of these classes consisted of ~25,500 particles and
was refined to 4.1Å in RELION. Postprocessing was run on this data in RELION using
the same mask as previously with an applied b factor of -150, leading to a final
resolution of 4.0Å (Supplementary Figure 3.4). Local resolutions were estimated using
RESMAP75.
CaM-bound TRPV5
For the CaM-bound dataset, MotionCorr273 was used without gain correction
and without binning to produce both summed and dose weighted micrographs with a
final pixel size of 1.1Å. CTF estimation of the summed micrographs was preformed
using Gctf74. All other image processing was performed using RELION on the dose
weighted micrographs unless otherwise mentioned60,103. To create templates for
autopicking, 3,125 particles were manually picked from 2,118 micrographs and sorted
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into 30 classes. The best classes were used to autopick 391,648 particles which were
then subjected to 2D classification into 100 classes to remove false positives and
suboptimal particles. The best classes contained 153,776 particles, which were refined
to 5.4Å using 3D AutoRefine with C1 symmetry in the absence of a mask using the
same initial model as in the lipid-bound structure. At this point, there was clearly density
present in the region between the ankyrin repeat domains of the TRPV5 monomers, but
it appeared to be asymmetrical.
To make sure that information for all the asymmetrical features was aligned in
the same orientation, we decided to use symmetry expansion. The ~154,000 particles
from the initial C1 reconstruction were refined in C4 to generate symmetry operators.
Relion symmetry expansion in C4 was used to expand the particle stack and ensure that
all the information for CaM was present in all four possible orientations. A sphere of
radius 25Å was created in Chimera and placed at the base of the pore so that the entire
region with density for CaM was in the sphere. A mask was made of this sphere in
RELION, at a threshold of 0.1, extended by 5 pixels, and with a soft edge of 5 pixels.
This spherical mask was used for particle subtraction, as described above, and then the
subtracted particles were sorted into 5 classes with 3D classification.

The resulting

classes captured CaM in the 4 possible orientations, with approximately equal numbers
of particles, as well as a class without CaM bound. The class with the best resolution
was chosen, consisting of ~129,000 particles, and we reverted to the unsubtracted
particles and refined these particles. There was still some heterogeneity in the CaM, so
we further classified the particles into 3 classes, resulting in a class with ~47,500
particles that refined to 4.7Å in RELION.
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After postprocessing in RELION with an

applied b factor of -200, the, this data reached a resolution of 4.4Å (Supplementary
Figure 3.11). Local resolutions were estimated using RESMAP75.
Model Building
The previously published model of TRPV5 bound to econazole (PDB 6B5V)27
was used as an initial model and docked to the cryo-EM map of lipid-bound TRPV5. The
model was manually adjusted in Coot77 and refined with imposed 4 fold NCS using
phenix.real_space_refinement115. The lipid-bound TRPV5 model was docked into the
PI(4,5)P2-bound TRPV5 map and manually adjusted and refined as before. The lipidbound TRPV5 model was docked into the CaM-bound TRPV5 map. To model CaM into
the extra density, the N-lobe (residues 6-77) and C-lobe (residues 83-147) of a calciumbound CaM structure (PDB 1CLL) were separated and independently fit in Chimera to
the two lobes of density visible at the base of the pore. A portion of the N-lobe was
visible only as broken density, and so was removed from the model. The TRPV5 Cterminal peptide from state 01 of PDB 5OEO was fit into the remaining density near the
C-lobe in Chimera. An extension of the C-terminus of TRPV5 chain A was modeled into
helical density in the peptide binding pocket of the CaM N-Lobe. This assembly was
manually adjusted in Coot and refined without NCS using phenix.real_space_refinement.
The final models were randomized in PHENIX115 by 0.5Å and refined against one
of the half maps. EMAN2 was used to generate FSC curves between this refined test
model and each half map as well as between the final model and the summed map for
each model. The pore radii were generated using HOLE116. Figures were made in
Pymol117 and Chimera118.
Xenopus oocyte electrophysiology
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Oocyte sacs were extracted from female Xenopus laevis frogs (Xenopus
Express) and digested with 0.2 mg/ml collagenase (Sigma) in OR2 solution (82.5 mM
NaCl, 2 mM KCl, 1 mM MgCl2, and 5 mM HEPES, pH 7.4) overnight at 18 °C. Oocytes
were maintained in OR2 solution plus 1.8 mM CaCl2 and 1% penicillin/streptomycin
(Mediatech) at 18 °C. cRNA was generated using the mMessage mMachine kit (Thermo
Fisher); point mutations were introduced using the Quikchange mutagenesis kit (Agilent
Genomics). cRNA (20 ng) was injected using a nanoliter injector system (World
Precision Instruments). The W583L mutant of TRPV5 was kept in OR2 with 0.1 mM
CaCl2, to avoid Ca2+ overload and cell damage. The experiments were performed 48-72
h after injection. Purified calmodulin from bovine testes was purchased from Sigma.
Two-electrode voltage clamp (TEVC) measurements were performed as
described earlier71; briefly oocytes were initially placed in a solution containing 97 mM
NaCl, 2 mM KCl, 1 mM MgCl2, and 5 mM HEPES, pH 7.4, where TRPV5 or TRPV6
currents are largely blocked by Mg2+ and trace amounts of Ca2+ in the medium.
Monovalent currents were initiated with changing the solution containing 96 mM LiCl, 1
mM EGTA, and 5 mM HEPES, pH 7.4. Currents were recorded with thin-wall inner
filament-containing glass pipettes (World Precision Instruments) filled with 3 M KCl in 1%
agarose. Currents were recorded with a GeneClamp 500B amplifier (Molecular Devices
using a ramp protocol from – 100 to + 100 mV (0.25 mV/ms), immediately preceded by a
100-ms step to − 100 mV, applied once every second; holding potential was 0 mV.
Excised inside-out patch clamp experiments were performed as described
earlier101 using borosilicate glass pipettes (World Precision Instruments) of 0.8–1.7
megaohm resistance. The electrode pipette solution contained 96 mM LiCl, 1 mM EGTA,
and 5 mM HEPES, pH 7.4. After establishing giagohm resistance seals on devitellinized
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Xenopus oocytes, the currents were measured using an Axopath 200B amplifier
(Molecular Devices). We used a ramp protocol from -100 mV to 100 mV, performed
once a second, immediately preceded by a 100-ms step to -100 mV. The perfusion
solution contained 93 mM potassium gluconate, 5 mM HEDTA, 5 mM HEPES, with the
pH adjusted to 7.4. To obtain 3 μM free Ca2+, 2.5 mM Ca2+ gluconate was added. The
bath was connected with the ground electrode through an agar bridge.
TRPV6 structural modeling, docking simulations and molecular dynamics
simulations
We generated an almost full-length atomistic model of TRPV6 by performing
comparative homology modeling using the structure of the closed state of TRPV1 as a
template (PDB:3J5P). We extracted the pairwise sequence alignment between
TRPV1 and TRPV6 from the multiple sequence alignment containing about 3,000
sequences119. We then generated 288 models using ROSETTA 120 and discarded the
50 ones with the lowest score. We performed clustering on the remaining 248
structures and found two major clusters differing by the conformation of the S2-S3
segment. Due to the absence of significant structural constraints from the template,
we modeled this region of TRPV6 ab initio.
To investigate the binding mode of PI(4,5)P 2 we considered a model ligand
and performed a series of stochastic optimizations of its positions with respect to the
TRPV6 structure using the program AUTODOCK 121. The model ligand is a simplified
version PI(4,5)P2 that contains the entire head group, the glycerol moiety and part of
the acyl chains (up to the third carbon atom). This choice allowed us to explore
thoroughly the conformational space by ignoring the large number of degrees of
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freedom describing the configuration of the flexible acyl chain. Since not all the
binding poses of the model ligand correspond to a geometrically viable conformation
of PI(4,5)P2, we post-processed the output of docking and selected only those binding
poses in which the acyl chain is correctly positioned with respect to the lipid bilayer.
The conformational search was restricted to a specific region of the channel
encompassing the S4-S5 linker, the N-term sections of S1, S3 and S5, the C-term
section and S2 and S4, the S2-S3 loop, the N-term section of the TRP box and the
adjacent part of the cytoplasmic domain. The region was large enough to contain at
least two adjacent subunits to allow for the identification of potential interactions at
their interface. For each structure of TRPV6 (20 in total) 1,000 docking experiments
were performed using the Lamarckian genetic algorithm allowing for a maximum of
250,000 energy evaluations.
We performed molecular dynamics simulations of the PI(4,5)P2-TRPV6 and
PI(4,5)P2-TRPV1 complexes and of the TRPV6 apo channel (with no bound
PI(4,5)P2). As initial configurations, we considered the structural models with the
highest scores. The channels were embedded into a fully hydrated 1-palmitoyl-2oleoyl-sn-glycero-3-phosphocholine membrane surrounded by a 150 mM KCl solution.
Overall, the system contains more than 300,000 atoms. During the initial equilibration
protocol, we gradually released each component of the (water and ions, lipid tails,
lipid head groups, protein side chains and protein backbone) system from positional
restraints. During the production run, trajectories were collected for 0.7 μs.
Simulations were performed at constant temperature and pressure (1 atm, 300K)
using the Langevin piston approach using NAMD 2.10122. The CHARMM36 force
field123 was used to describe the protein, the ions and the lipid molecules. For the
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vdW interactions, we used a cutoff of 11 Å with a switching function between 8 and 11
Å. The long-range component of electrostatic interactions was calculated using the
Particle Mesh Ewald approach124 using a cutoff for the short-range component of 11
Å. The equations of motion were integrated using the RESPA multiple time-step
algorithm125, with a time step of 2 fs and long-range interactions calculated every
other step.
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3.6 Figures

Figure

3.1.

Lipid-bound

TRPV5

structure

in

detergent.

(A)

A

schematic

representation of the TRPV5 domains per channel monomer. Dashed lines indicate
regions for which a model could not be built. (B) Density map of lipid-bound TRPV5 at
3.9Å resolution. Density for TRPV5 is shown in grey and the densities attributed to
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annular lipids are shown in khaki. (C) Cartoon representation of the lipid-bound TRPV5
model. The TRPV5 tetramer is depicted as pink cartoons and annular lipids as khaki
sticks. (D) Cartoon representation of the lipid-bound TRPV5 pore highlighting the three
constriction points in the selectivity filter and lower gate. (E) Plot of pore radii of lipidbound TRPV5 as a function of distance through the pore. The dotted line indicates the
radius of a dehydrated calcium ion.
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Figure

3.2.

PI(4,5)P2-bound

TRPV5

structure

and

PI(4,5)P2-bound

TRPV6

modelling. (A) The initial reconstruction of PI(4,5)P2-bound TRPV5 in nanodiscs before
masking and 3D classification. TRPV5 density is shown in gray, annular lipids are shown
in khaki, and PI(4,5)P2 is shown in orange. (B) PI(4,5)P2-bound TRPV5 cryo-EM density
in nanodiscs after focused 3D classification. TRPV5 density is shown in gray, annular
lipids are shown in khaki, and PI(4,5)P2 is shown in orange. (C) Zoomed-in view of the
TRPV5 PI(4,5)P2-binding pocket. The PI(4,5)P2-binding site in the TRPV5 channel is
located between the N-linker (R302, R305), S4-S5 linker (K484), and the S6 helix
(R584) of the channel. (D) A model produced by MD simulations of the predicted
interaction between the homologous TRPV6 channel and PI(4,5)P2. (E) Neutralization of
key PI(4,5)P2 interacting residues increases sensitivity to depletion of PI(4,5)P2 in
TRPV6. The TRPV6 currents in oocytes measured before and after incubation with 35
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μM wortmannin for 1 h. Current values after wortmannin treatment are normalized to
current values before treatment. P-values for significance values are shown after
rounding to the first non-zero digit (analysis of variance). (F) Neutralization of key
PI(4,5)P2 interacting residues increases sensitivity to depletion of PI(4,5)P2 in TRPV5.
The TRPV5 currents in oocytes measured before and after incubation with 35 μM
wortmannin for 1 h. Current values after wortmannin treatment are normalized to current
values before treatment. P-values for significance values are shown after rounding to the
first non-zero digit (analysis of variance). The sample size (n) indicates the number of
individual oocytes tested, from at least two different oocyte preparations. Error bars
represent ±SEM.
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Figure 3.3. Comparison between lipid-bound and PI(4,5)P2-bound TRPV5. (A) The
pore diagram of PI(4,5)P2-bound TRPV5 is shown in green. (B) Lipid-bound TRPV5
(pink) superimposed onto the PI(4,5)P2-bound (green) pore diagram shows a slight shift
in the S6 helices and important gating residues originating at the π-helix. (C) Plot of pore
radii of lipid-bound TRPV5 (pink) and PI(4,5)P2-bound TRPV5 (green) as a function of
distance through the pore. The dotted line indicates the radius of a calcium ion. (D)
Extracellular view of the tetrameric selectivity filter of lipid-bound (pink) and PI(4,5)P2bound TRPV5 (green). (E) Intracellular view of the tetrameric lower gate of lipid-bound
(pink) and PI(4,5)P2-bound TRPV5 (green). (F) Zoomed in view of the overlayed TMDs
of lipid-bound (pink) and PI(4,5)P2-bound TRPV5 (green). DiC8 PI(4,5)P2 is shown in
orange sticks.
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Figure 3.4. Interactions of TRPV5 with PI(4,5)P2 . (A) View of the lower S6 helix and
TRP domain of PI(4,5)P2-bound TRPV5. The PI(4,5)P2-bound TRPV5 is shown in green
and the PI(4,5)P2 in orange. (B) View of the lower S6 helix and TRP domain of the lipidbound TRPV5 structure (pink). (C) The 5’ phosphate of PI(4,5)P2 (orange) interacts with
R302 of the N-linker and K484 of the S4-S5 linker in the PI(4,5)P2-bound TRPV5
structure. (D) The lipid-bound structure showing the N-linker, S4-S5 linker, S6 helix and
TRP domain in pink.
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Figure 3.5. CaM-bound structure of TRPV5. (A) Side and bottom view of the CaMbound TRPV5 density map at 4.4 Å resolution. Density for TRPV5 is shown in grey,
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annular lipids shown in khaki, and CaM shown in hot pink. (B) Cartoon representation of
the CaM-bound TRPV5 model in a side and bottom view. TRPV5 is shown in blue and
CaM is shown in hot pink. (C) Pore diagram of CaM-bound TRPV5. Constriction
residues are labeled and shown as sticks. (D) Plot of pore radii of CaM-bound TRPV5 as
a function of distance through the pore is shown in blue. For reference, the lipid-bound
TRPV5 pore graph is shown in pink. The dotted line indicates the radius of a calcium ion.
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Figure 3.6. Mechanism of TRPV5 inactivation by CaM. (A) Structure of rat CaM
bound to TRPV5 C-terminus fragments. Both the N-lobe and C-lobe were visualized
along with N640-K652 and H699-T709 of TRPV5. CaM is shown in hot pink, and TRPV5
is shown in blue. Calcium ions bound to the N-lobes and C-lobes of CaM are shown as
green spheres. (B) CaM interaction with chain A of TRPV5. (C) CaM C-lobe interaction
with W702 on the TRPV5 C-terminus. (D) CaM N-lobe makes multiple hydrophobic
interactions along N640-K652. (E) The base of the TRPV5 pore is shown with K116 of
CaM bound at W583, causing a steric blockage of calcium flow. (F) The excised inside
out patch clamp experiments show that wild type TRPV5 is inhibited upon addition of
Ca2+ activated CaM. Representative current trace is at −100 mV; the applications of 25
μM diC8 PI(4,5)P2, 0.2 μM CaM and 3 μM free Ca2+ are indicated by the horizontal lines.
(G) The excised inside out patch clamp experiments show that Ca2+-activated CaM did
not inhibit the W583L TRPV5 mutant. Representative current trace is at −100 mV; the
applications of 25 μM diC8 PI(4,5)P2, 0.2 μM CaM and 3 μM free Ca2+ are indicated by
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the horizontal lines. (H) Summary of the data, current amplitudes after CaM were divided
by current values before CaM applications, P = 0.011 (two-sample t-test). The sample
size (n) indicates the number of individual patches tested, each obtained from a different
oocyte. Error bars represent ±SEM.
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Figure 3.7. TRPV5 activation by PI(4,5)P2 and inactivation by CaM. A schematic
representation of the proposed binding of both PI(4,5)P2 and CaM to TRPV5, inducing
either channel activation or inactivation. A dimer of TRPV5 is shown as a grey diagram,
PI(4,5)P2 is shown in orange, CaM is shown in pink and the blue circles indicate the flow
of calcium ions.
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Table 3.1. Cryo-EM data collection, refinement and validation.

Data collection and
processing
Magnification
Voltage (kV)
Defocus range (μm)
Pixel size (Å)
Symmetry imposed
Initial particle images (no.)
Final particle images (no.)
Map resolution (Å)
FSC threshold
Map resolution range (Å)
Refinement
Model resolution cut-off (Å)
FSC threshold
Map sharpening B factor (Å2)
Model composition
Nonhydrogen atoms
Protein residues
Ligands
R.m.s. deviations
Bond lengths (Å)
Bond angles (°)
Validation
MolProbity score
Clashscore
Poor rotamers (%)
Ramachandran plot
Favored (%)
Allowed (%)
Disallowed (%)

Lipid-Bound
TRPV5 in
Detergent
(EMB-7965,
PDB 6DMR)

PI(4,5)P2-Bound
TRPV5 in
Nanodiscs
(EMB-7966,
PDB 6DMU)

CaM-Bound
TRPV5 in
Detergent
(EMB-7967 ,
PDB 6DMW)

~45,500
300
1.0-2.5
1.1
C4
>1.5 million
45,354
3.9
0.143
3.0-5.0

~45,500
300
1.0-2.5
1.1
C4
493,047
25,538
4.0
0.143
3.0-5.0

~45,500
300
1.25-2.5
1.1
C1
391,648
47,484
4.4
0.143
3.0-5.0

3.9
0.143
-174

4.0
0.143
-150

4.4
0.143
-200

0
2424
0

0
2428
4

3
2562
0

0.006
1.18

0.004
0.873

0.005
0.92

1.44
3.57
0.00

2.20
23.13
0.00

1.64
6.63
0.18

95.76
4.24
0.00

95.07
4.93
0.00

95.98
4.02
0.00
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Supplementary Figure 3.1. Lipid-bound TRPV5 structure in detergent. (A) A
representative micrograph and 2D classes for lipid-bound TRPV5. (B) FSC curves for
the masked (green), unmasked (red) and corrected (blue) maps (top). The dotted line
indicates an FSC of 0.143. FSC curves comparing the model to density maps (bottom).
(C) The angular distribution of views is shown for the C4 refined map. (D) Local
resolution is shown for lipid-bound TRPV5 in three different orientations on a scale of 3.0
Å (blue) to 5.0 Å (red).
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Supplementary Figure 3.2. Lipid-bound TRPV5 data processing. The workflow used
to solve the lipid-bound TRPV5 structure to 3.9Å in detergent.
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Supplementary Figure 3.3. Lipid-bound TRPV5 model. Various helices of the lipidbound TRPV5 model (pink ribbon) overlaid with the lipid-bound TRPV5 density map
(mesh). Residues are shown as sticks to illustrate the accuracy of the model. All helices
shown are within the 3.0 - 4.0 Å region of the structure.
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Supplementary Figure 3.4. TRPV5 nanodisc data processing. The workflow used to
reconstruct the PI(4,5)P2-bound structure of TRPV5 at 4.0 Å resolution and the lipidbound TRPV5 structure at 4.4 Å resolution in nanodiscs. The TRPV5 data in nanodiscs
was initially collected and refined at 4.3 Å resolution (Initial 3D Reconstruction). Using
multiple rounds of focused 3D classification, a 4.0 Å structure of PI(4,5)P2-bound
TRPV5, and a 4.4Å structure of lipid-bound TRPV5 were obtained.
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Supplementary Figure 3.5. Lipid-bound TRPV5 structure in nanodiscs. (A) Density
map of lipid-bound TRPV5 at 4.4 Å resolution in nanodiscs. Density for TRPV5 is shown
in grey and the densities attributed to annular lipids are shown in khaki. (B) FSC curves
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for the masked (green), unmasked (red) and corrected (blue) maps. The dotted line
indicates an FSC of 0.143. (C) The angular distribution of views is shown for the C4
refined map. (D) Local resolution is shown for lipid-bound TRPV5 in nanodiscs in three
different orientations on a scale of 3.0 Å (blue) to 5.0 Å (red). (E) Comparison between
lipid-bound TRPV5 structures in nanodiscs and detergent at the lower gate region. (F)
Comparison between lipid-bound and PI(4,5)P2-bound TRPV5 structures in nanodiscs at
the lower gate region.
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Supplementary Figure 3.6. PI(4,5)P2-bound TRPV5 structure in nanodiscs. (A) A
representative micrograph and 2D classes for PI(4,5)P2-bound TRPV5 in nanodiscs. (B)
FSC curves for the masked (green), unmasked (red) and corrected (blue) maps (top).
The dotted line indicates an FSC of 0.143. FSC curves comparing the model to density
maps (bottom). (C) The angular distribution of views is shown for the C4 refined map.
(D) Local resolution is shown for PI(4,5)P2-bound TRPV5 in three different orientations
on a scale of 3.0Å (blue) to 5.0Å (red).
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Supplementary Figure 3.7. PI(4,5)P2-bound TRPV5 model. Various helices of the
PI(4,5)P2-bound TRPV5 model (green ribbon) overlaid with the PI(4,5)P2-bound TRPV5
density map (mesh). Residues are shown as sticks to illustrate the accuracy of the
model. All helices shown are within the 3.0 - 4.0 Å region of the structure.
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Supplementary Figure 3.8. TRPV6 MD model and possible binding sites for
PI(4,5)P2 . (A) Possible loop trajectories are seen between the S2 and S3 helices in two
major conformations denoted in red and blue (left). Energy refined model for
conformation 1 (center). Energy refined model for conformation 2 (right). (B) Plot of
changes in RMSD as a function of time between PI(4,5)P2 and apo structures of the
model (left). Plot of changes in RMSD as a function of time between four PI(4,5)P5
binding sites. (C) MD model representation of PI(4,5)P2 bound to TRPV6. Depicted in
grey is TRPV6, in red is PI(4,5)P2 , and in cyan are phospholipids.
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Supplementary Figure 3.9. Representative current traces and raw current
amplitudes for TRPV6, TRPV5 and their mutants. Two electrode voltage clamp
measurements were performed as described in the methods section on Xenopus
oocytes expressing TRPV6, TRPV5 or their mutants. (A) and (B) show representative
traces for TRPV6 and its R302Q mutant, monovalent currents were induced by exposing
oocytes to a Ca2+ and Mg2+ free solution. After currents were measured, oocytes were
incubated with 35 μM wortmannin for 1hr and currents were measured again in the same
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oocytes (right panels). Summary data for these mutants as well as for other TRPV6 and
TRPV5 mutants is shown in Figure 3.2E and 3.2F (C) Raw current amplitudes of TRPV6
and its mutants. P-values for significance values are shown after rounding to the first
non-zero digit (analysis of variance). (D) Raw current amplitudes for TRPV5 and its
mutants, p=0.11 and 0.75 for the difference between TRPV5 and R302Q and K484Q
respectively (analysis of variance). The sample size (n) indicates the number of
individual oocytes tested from at least two different oocyte preparations. Error bars
represent +/- S.E.M.
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Supplementary Figure 3.10. CaM-bound TRPV5 structure. (A) A representative
micrograph and 2D classes for CaM-bound TRPV5. (B) FSC curves for the masked
(green), unmasked (red) and corrected (blue) maps (top).The dotted line indicates an
FSC of 0.143. FSC curves comparing the model to density maps (bottom). (C) The
angular distribution of views is shown for the C1 refined map. (D) Local resolution is
shown for CaM-bound TRPV5 in three different orientations on a scale of 3.0Å (blue) to
5.0Å (red).

110

Supplementary Figure 3.11. CaM-bound TRPV5 data processing. The workflow used
to solve the C1 symmetric CaM-bound TRPV5 structure to 4.4Å.
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Supplementary Figure 3.12. CaM-bound TRPV5 model. Various helices of the CaMbound TRPV5 model (ribbon, blue for TRPV5 and hot pink for CaM) overlaid with the
CaM-bound TRPV5 density map (mesh). Residues are shown as sticks to illustrate the
accuracy of the model. All helices shown are within the 3.0 - 4.0 Å region of the
structure. CaM and TRPV5 C-terminal binding partners shown only as ribbons.
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4.1 Abstract
Transient receptor potential vanilloid 5 (TRPV5) is a highly calcium selective ion
channel that acts as the rate limiting step of calcium reabsorption in the body. Lack of
potent specific modulators of TRPV5 has limited the ability to probe the contribution of
TRPV5 in disease phenotypes such as hypercalcemia and nephrolithiasis. Here, we
performed structure-based virtual screening (SBVS) of a compound library obtained from
ZINC15 database, and identified two potent inhibitors of TRPV5, one of which exhibits
selectivity for TRPV5 over its close homologue, TRPV6. Structural characterization of
these inhibitors using cryo-electron microscopy has allowed us to identify two novel
binding sites for TRPV5. Structural and functional analysis have given us insights into
the mechanism of action of these inhibitors and laid the groundwork for rational design of
other selective modulators of TRPV5.
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4.2 Introduction
TRPV5 is a calcium selective ion channel that is responsible for the fine-tuning of
calcium reabsorption in the kidney and has been shown to be a critical component of
systemic calcium homeostasis2,13,20,126. Due to its role in calcium handling, potent and
specific chemical modulators of TRPV5 have the potential to aid in treatments of calcium
homeostasis disorders such as nephrolithiasis and hypercalcemia40. By uncovering
specific modulators of TRPV5 it would be possible to identify the contribution of TRPV5
in these disease phenotypes and provide a foundation of targeted treatments.
Additionally, chemical probes of TRPV5 could aid in identifying its roll in cell types where
it is expressed in low abundance or in cell types that express both TRPV5 and its close
homologue TRPV6. While there are several synthetic modulators of TRPV5 including
econazole, TH-1177, and select cannabinoids, all have reported potencies in the midmicromolar range and currently none have robust selectivity for TRPV5 over TRPV6 and
the other TRPV subfamily channels26,30,127.
Endogenous TRPV5 activity has been well documented using both structural and
functional methods128. In the cell, binding of PI(4,5)P2 is critical for single channel
opening while rapid desensitization occurs via binding of calmodulin (CaM) to the base
of the pore13,43,128,129. Thus small activators that bind directly to TRPV5 are expected to
act by allosterically enhancing conductance during PI(4,5)P2 activation, mimicking
PI(4,5)P2 activation or decreasing CaM induced desensitization. On the other hand,
synthetic inhibitors that bind to TRPV5 are expected to act by directly blocking PI(4,5)P2
binding, allosterically limiting the conformational changes induced by PI(4,5)P2 binding,
directly blocking ion flow by binding in the pore or by increasing the desensitization of
TRPV5 by CaM. Due to the conserved nature of PI(4,5)P2 and CaM modulation within
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the TRP channel family, allosteric modulators are more likely to be both potent and
specific for TRPV521,104,130.
Structure-based virtual screening (SBVS) has led to the discovery of many novel
compounds over the years, and it has been extensively used wherein structural
information has been abundant such as for the GPCR field131. With recent
advancements in compound libraries and screening technology, SBVS is now an
incredible tool that allows for the rapid identification of potential modulators of structural
targets from within libraries of millions of compounds132. Due to the recent availability of
high resolution TRPV5 cryo-EM structures we were able to utilize this technique to
uncover novel modulators of TRPV5. We screened the econazole-binding pocket of
TRPV5, which was reported in the same location as the vanilloid binding pocket in
TRPV127. This allosteric binding site has been reported to bind modulators such as small
molecules and lipids in several TRPV subfamily channels27,63,128. Through this screen we
identified two novel synthetic inhibitors that to our best knowledge have not been
previously characterized as a modulator for any protein.
4.3 Results
In silico compound screening
Currently several structures of TRPV5 are available with a variety of modulators
bound27,128. The econazole-bound TRPV5 structure revealed that the small molecule
inhibitor of TRPV5, econazole, bound in the “vanilloid” pocket of TRPV5 which is a welldocumented site of modulator binding in other TRPV channels27,63. This pocket was
resolved to a higher resolution (~3.0Å local resolution) in the lipid-bound TRPV5128 which
allowed for SBVS in this pocket which we predicted would yield other chemical inhibitors
of TRPV5. This inhibitor binding pocket is located at the interface of two adjacent
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monomers and is composed of the S3, S4 and S4-S5 linker of one monomer and the S5
and S6 helices of the second monomer (Supplementary Figure 4.1). The resolution of
this pocket in the lipid-bound TRPV5 structure allowed for unambiguous backbone
placement and confident side chain placement. Using the Schrodinger suite 2018-1, the
ZINC15 “Drugs Now” library consisting of ~12 million compounds were docked into this
pocket. The top 100 compounds as ranked by their docking score were grouped based
on their chemical similarity using Tanimoto similarity scores of ECFP4 binary fingerprints
into 65 clusters of unique chemical scaffolds. Notably, none of the top 100 compounds
exhibited significant similarity (defined by a Tanimoto similarity score larger than 0.4)
with econazole or known TRPV6 inhibitors. Of the 65 unique chemical scaffolds, 42
representative compounds were readily available for purchase.
Functional validation of compound hits
These 42 compounds were screened in HEK293 cells expressing rabbit TRPV5
using whole cell patch clamp experiments to measure modulation of monovalent
currents through TRPV5. Each compound was tested at 10 μM or 3 μM and most of
them showed no clear inhibition or potentiation of TRPV5 currents (Supplemental Figure
4.2). See Supplemental Table 4.1 for the list of compounds that had no effect. One of
the compounds, ZINC9155420 showed robust (~80%) inhibition of rabbit TRPV5 at 10
µM, but did not appear to have any selectivity for TRPV5 over the closely related TRPV6
channels (Figure 4.1A-C). The IC50 of ZINC9155420 for rbTRPV5 inhibition was 2.91 ±
0.56 µM, which is of comparable potency to econazole26,27 (Figure 4.1A-C). This
compound also inhibited the hTRPV6 channel with a comparable IC50 (4.05 ± 1.04 μM).
ZINC9155420 is chemically distinct from other reported inhibitors of TRPV channels and
has not been previously reported as a modulator of any protein.
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Five chemical analogues of ZINC9155420 were available for purchase and we
tested them using the HEK293 cell expression system, which revealed a second potent
inhibitor, ZINC17988990. This compound exhibited robust inhibition of rabbit TRPV5 with
an IC50 of 106 ± 27 nM while also showing marked selectivity for TRPV5 over TRPV6
(Figure 4.1D-E). Human TRPV6 was not inhibited by ZINC17988990 at concentrations
up to 10 µM. Additionally, ZINC17988990 had no activity on other TRP channels tested
(TRPV1, TRPV3, TRPV4 and TRPM8) at low concentrations (1-3 µM), but did exhibit
moderate inhibition on TRPV3 and TRPM8 at concentrations above 10 µM
(Supplementary Figure 4.3). Further characterization of ZINC17988990 revealed that it
has comparable inhibition of the human isoform of TRPV5 (IC50=177 ± 47 nM)
(Supplementary Figure 4.4). We also tested the effect of ZINC17988990 on rbTRPV5
expressed in Xenopus oocytes (Supplementary Figure 4.5). Similar to our previous
results with econazole, the concentrations required to achieve inhibition were higher in
oocytes (IC50 = 4.37 ± 0.69 μM) compared to HEK293 cells. Similar to our results in HEK
cells, ZINC17988990 did not induce any inhibition of hTRPV6, up to 30 μM
(Supplementary Figure 4.5). ZINC17988990 has also not been previously reported as a
modulator of any protein. An additional compound, ZINC05626366 also inhibited TRPV5
channels with a potency similar to the less potent ZINC9155420 (Supplementary Figure
4.6); we did not characterize this compound further.
Structural determination of novel TRPV5 inhibitors
In order to probe the mechanism of action of these new inhibitors, we utilized
cryo-electron microscopy (cryo-EM) to solve the structure of rabbit TRPV5 in the
presence of each of these compounds. We were able to resolve nanodisc reconstituted
TRPV5 in the presence of 10µM ZINC9155420 or ZINC17988990 to 4.3Å and 3.8Å,
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respectively (Figure 4.2, Supplementary Figure 4.7-4.10, Table 4.1). These structures of
TRPV5 are consistent with the architecture of the previously reported structures of
TRPV527,128. The transmembrane domain (TMD) consists of transmembrane helices 1-4
(S1-S4) bundled in a voltage sensing-like domain with helices 5 and 6 (S5 and S6)
domain swapped to create the pore of the channel and a large intracellular ankyrin
repeat domain (ARD). Higher local resolution in the TMD of both structures allowed for
the confident placement of side chains in this region when building the model
(Supplementary Figure 4.7-4.10). The lower resolution ARD of both structures allowed
for

confident

carbon

backbone

placement

(Supplementary

Figure

4.7-4.10).

Unambiguous non-protein densities in both structures that had not been identified in
previously reported cryo-EM TRPV5 structures were attributed to the bound compounds
(Figure 4.2). Interestingly, neither compound appeared to bind in the econazole binding
pocket. Rather, in both structures this pocket appears to be occupied by a tightly bound
lipid molecule. This is likely due to the high hydrophobicity of the binding pocket
screened coupled with the abundance of hydrophobic pockets available in the TMD of
TRPV5.
In the ZINC9155420-bound TRPV5 structure the compound density is located at
the interface between the S4-S5 linker of one monomer and the S6 helix of an adjacent
monomer (Figure 4.3). This density is found in both half maps and the sharpened
density map in the ZINC9155420-bound structure and has not been seen in other
TRPV5 cryo-EM structures to date (Supplementary Figure 4.11). Additionally, two strong
lipid densities appear to bracket the compound and may also be involved in compound
binding (Figure 4.3). ZINC9155420 was purchased as a racemic mixture and therefore
the functional and structural screens were not able to determine which of the
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stereoisomers exhibited the inhibitory effect. Based on the fit to the density the Senantiomer of ZINC9155420 was docked into the model. The lack of selectivity of this
molecule is likely due to the extremely high level of sequence homology of this region
between TRPV5 and TRPV6 (Supplementary Figure 4.12). This S4-S5 linker has been
shown to be critical for gating of several TRP channels and may be evolutionarily
conserved due to its essential role in channel function. Though this binding site is near
the econazole pocket there are no residues that overlap with the predicted and observed
binding pockets (Supplementary Figure 4.13), likely because the virtual screening was
performed in the econazole pocket in the absence of bound lipid.
The ZINC17988990-bound TRPV5 structure revealed two densities that could be
attributed to bound compound. One, like in the ZINC9155420-bound structure, was
located at the interface of the S4-S5 linker of one monomer and the S6 helix of an
adjacent monomer (Supplementary Figure 4.13). This density, though strong in the
sharpened cryo-EM density map, was not consistently visible in the half-maps and
therefore is likely not the primary binding site of this compound (Supplementary Figure
4.11). The second binding site is located between the intracellular half of the S1-S4
bundle and the TRP helix. Though this pocket has been consistently occupied by lipids
in the previous TRPV5 channel structures, density lower in this pocket has been
identified for the first time in this structure (Figure 4.4, Supplementary Figure 4.14). This
pocket has also been identified in TRPM8 and TRPV6 to bind ligands133,134.
The two inhibitors are chemically similar with one of the key differences being the
presence of two chirality centers in ZINC9155420 while ZINC17988990 has none.
Therefore, the binding of both compounds is expected in a highly exposed binding site
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like the one located at the S4-S5 linker. The limited flexibility of ZINC9155420 due to the
chirality centers may hinder the binding in the tightly packed S1-S4 bundle (Figure 4.1).
Selective inhibition of TRPV5
The residues that constitute the binding site in the S1-S4 bundle of the
ZINC17988990-bound TRPV5 structure include E403, D406, Y415, Y467 and F468
(Figure 4.4). Of these residues that make contact with the compound density in the EM
map, only Y415 is not conserved between TRPV5 and TRPV6 (Supplementary Figure
4.12). In TRPV6 the residue at this position is a phenylalanine. Based on the docking of
this compound in our model D406 makes a hydrogen bond with the amide group on the
thienopyrimidinone ring while Y415 is making pi-pi interactions with the aromatic ring of
that same moiety. In order to functionally confirm that this pocket is involved in
compound binding we tested the inhibition of ZINC17988990 on F468A, D406A and
Y415F mutations of TRPV5 (Figure 4.4). The F468A mutation created a non-functional
channel implying this residue is important for proper protein folding, trafficking to the
membrane and/or activation by PI(4,5)P2 (data not shown). The D406A mutation
eliminated inhibition of the channel at low concentrations while maintaining the inhibitory
effect at high concentrations, resulting in an IC50 of 3.68 ± 1.03 μM. The Y415F mutation
also results in a reduced potency of ZINC17988990, resulting in an IC50 of 0.644 ± 0.106
μM. The reduced inhibitory effects of these mutant channels provide evidence that the
compound is binding in and can exhibit inhibitory effect from this pocket.
A comparison of this binding pocket in TRPV5 and TRPV6 shows very high
sequence homology and therefore the selectivity of ZINC17988990 is not likely due to a
difference in sequence (Supplementary Figure 4.12). Rather it appears that the
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structural difference between TRPV5 and TRPV6 in this region may play a role. The 16
amino acid linker between the S2 and S3 helices of TRPV5 has consistently been
resolved as a stable short helix, while in the many cryo-EM and x-ray crystallography
structures of TRPV6 this linker has not been resolved. This implies that the region is
extremely flexible in TRPV6 while it is consistently stable in TRPV5 (Supplementary
Figure 4.15). Both Y415 and D406 which make contacts with the drug density in the
ZINC17988990-bound TRPV5 structure are unresolved in all reported TRPV6 structures.
The lack of stability in this region in TRPV6 may not allow for those residues to contact
ZINC17988990 and thus not allow for effective inhibition.
This structure, in combination with the other previously solved TRPV5 structures
gives us insight as to how binding in the intracellular half of the S1-S4 bundle could lead
to channel inhibition. Large movements of the TRPV5 channel have been shown to
occur during PI(4,5)P2 induced channel opening128, specifically the rearrangement of the
lower S6 helix caused by the phosphate head group binding to R584 causes global
shifts in the protein from the lipid-bound closed pre-opened state (PDB: 6DMR) to the
opened PI(4,5)P2-bound state (PDB: 6DMU). While ZINC17988990-bound TRPV5
structure is similar to the lipid-bound closed pre-opened structure (RMSD 1.33) there are
several key differences between these two non-conducting states. First, the ion
conducting pore of the ZINC17988990-bound TRPV5 is closed at both the selectivity
filter (D542) and the lower gate (I575) whereas the lipid-bound TRPV5 channel is closed
only at the selectivity filter (Figure 4.5). Second, the S1-S4 bundle has undergone a shift
to accommodate the binding of ZINC17988990. Specifically, the S2 and S3 helices of
the ZINC17988990-bound TRPV5 have moved to bind the phenyl-thienopyrimidinone
moiety of ZINC17988990 which created a tighter space with in the intracellular section of
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the S1-S4 bundle. Residues E403, D406 and Y415 appear to move 1-2.5 Å (as
measured at the Cα) to accommodate binding while F468 and Y467 do not appear to
undergo conformational rearrangement (<1Å movement at the Cα).
Conformational changes undergone in the S1-S4 bundle upon PI(4,5)P2 binding
include movement away from the pore axis of all four helices with the largest movements
in the lower halves of the S1 and S2 helices (Figure 4.5). Additionally, a counter
clockwise rotation of the bundle and a pivot of the TRP helix occur accommodate the
helix transition at the base of the ion conduction pore (Figure 4.5). Based on the
positioning of ZINC17988990, these shifts and rotations would be limited by the
interaction of the compound with D406 and Y415 (Figure 4.5).

These stabilizing

interactions could act to lock this ZINC17988990-bound conformation in place and not
allow for the shifts in the S1-S4 bundle that are necessary for PI(4,5)P2 binding and
subsequent activation.
4.4 Conclusions
Here we have reported two novel TRPV5 inhibitors with low micromolar potency,
one of which is specific for TRPV5 over its close homologue TRPV6 as well as other
TRP family channels. Based on the cryo-EM structure we have identified two binding
sites one of which is the major binding site for the nonspecific compound ZINC9155420
located at the interface between lipids, the S4-S5 linker of one monomer and the S6
helix of an adjacent monomer. On the other hand, the specific inhibitor, ZINC17988990,
occupies a binding site in the intracellular half of the S1-S4 bundle. This binding site
partially overlaps with inhibitors seen in the recent TRPM8 structures135 as well as the 2APB binding site reported in for TRPV6134 (Supplementary Figure 4.16). 2-APB is a
small molecule inhibitor of TRPV6 which acts as an activator for other TRPV subfamily
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channels while having no effect on TRPV5 function134. The specificity of both 2-APB and
ZINC17988990 in spite of the high sequence homology in this pocket between TRPV5
and TRPV6 is likely due to the structural divergence of these channels in this region.
An analysis of other TRPV5 cryo-EM structures has provided insight in to a
potential mechanism of action of ZINC17988990 by locking TRPV5 in a closed
conformation that would not allow for the conformational changes necessary for
PI(4,5)P2 binding and subsequent activation. Binding of key residues such as D406 and
Y415 in the S1-S4 pocket that have not been seen to interact with any non-protein
density such as lipids in previous structures would limit movement in this region and
confer inhibition.
The success of this in silico screen has allowed for the discovery of two novel
inhibitors of TRPV5 that have the potential to be optimized for higher potency and
selectivity. Moreover, the identification of a binding site that allows for specificity of
TRPV5 over TRPV6 in spite of the high sequence homology now allows for a targeted in
silico screen in this pocket that has the potential to reveal additional small molecule
modulators of TRPV5. Overall, this study has laid the groundwork for the development
potent and specific inhibitors of TRPV5.
4.5 Methods
Structure-based virtual screening
The 4 Å resolution cryo-electron microscopy structure of the lipid-bound TRPV5
tetramer was used for structure-based virtual screening. The default protocol of the
Protein Prep Wizard in the Schrodinger suite 2018-1136 was followed to prepare the
protein for docking. Specifically, missing side chains and hydrogen atoms were added,
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side chain protonation states were assigned, and energy minimization was carried out
using the OPLS3 force-field137. Since the four monomers of TRPV5 are identical in the
starting TRPV5 tetramer structure, monomer A was chosen as a representative structure
to build a docking grid using the Schrodinger’s Receptor Grid generation tool, with the
grid centered at the lipid molecule’s center in the binding pocket of the protein monomer.
The box dimensions for the inner and outer grid boxes were 10 Å x 10 Å x 10 Å, and 30
Å x 30 Å x 30 Å, respectively.
The ZINC15 (http://zinc15.docking.org/) “Drugs Now” subset consisting of
11,768,355 compounds was downloaded and prepared for docking using the default
procedure in the Schrodinger’s Ligprep utility. Following ligand preparation and protein
grid generation, Glide was used to dock molecules of the “Drugs Now” subset in two
steps. First, Glide standard precision (SP) was used to preliminarily screen the ligand
library138,139. The top-ranked molecules based on Glide SP reached a docking score
plateau at -7.0. Secondly, the resulting 197,820 molecules were subjected to a Glide’s
extra precision (XP) refinement140. The top-ranked 100 molecules resulting from this
refinement were then grouped into 65 clusters based on their chemical similarity
calculated using Tanimoto similarity scores of ECFP4 binary fingerprints in the
Schrodinger’s Canvas program141,142. Notably, none of them exhibited significant
similarity (defined as Tanimoto similarity score larger than 0.4) with known inhibitors of
TRPV531,143.
Protein preparation
TRPV5 was expressed, purified and reconstituted into lipid nanodiscs as
previously reported128. In brief, rabbit TRPV5 was expressed in S. cerevisiae with a C125

terminal 1D4 epitope tag. Yeast cells were lysed using a microfluidizer and the
membranes were isolated via centrifugation at 3,000g, 14,000g and 100,000g. The
membranes were solubilized in buffer containing 20mM HEPES, pH 8.0, 150mM NaCl,
10% glycerol, 2mM TCEP, 1mM PMSF and 0.87mM LMNG. Insoluble material was
removed via ultracentrifugation. The solubilized TRPV5 was incubated with 1D4
conjugated CnBr-activated Sepharose 4B beads and washed with buffer containing
20mM HEPES, pH 8.0, 150mM NaCl, 2mM TCEP, and 0.064mM DMNG. Bound TRPV5
was eluted from the 1D4 beads with 20mM HEPES, pH 8.0, 150mM NaCl, 2mM TCEP,
0.064mM DMNG and 3mg/mL 1D4 peptide. TRPV5 was then reconstituted into
nanodiscs by combining TRPV5, MSP2N2 and soy polar lipids in a molar ratio of
1:1:200. Purified MSP2N2 was prepared using previously published methods. To
prepare the lipids, soy polar lipid extract (Avanti Polar Lipids, Inc.) were dried under
nitrogen flow for 3 hours and resuspended in buffer containing 20mM HEPES, pH 8.0,
150mM NaCl, 2mM TCEP and DMNG detergent at a molar ratio of 1:2.5 (lipids:DMNG).
The TRPV5, MSP2N2 and lipids were incubated for 30mins then Bio-Beads (Bio-Rad,
Bio-Beads SM-2 Absorbent Media) were added to the mixture for 1 hour. Fresh BioBeads were added and the mixture was allowed to incubate overnight with rotation. The
reconstituted nanodiscs were then passed over Superose 6 (GE Healthcare) sizeexclusion column equilibrated with 20mM HEPES, pH 8.0, 150mM NaCl, and 2mM
TCEP. The nanodisc reconstituted TRPV5 was concentrated to 2.2 mg/mL and
incubated with 10µM ZINC9155420 (Enamine Ltd.) or 10 µM of ZINC17988990
(Enamine Ltd.) prior to vitrification.
Cryo-EM data acquisition

126

Both TRPV5 nanodisc samples were incubated with 3mM F-Fos Choline 8
immediately before vitrification. Samples were double blotted on 1.2/1.3 Quantifoil Holey
Carbon grids (Quantifoil Micro Tools) with 3.5µL of sample per blot. The samples were
then vitrified in liquid ethane using a Vitrobot (Thermo Scientific). Both samples were
imaged on a Titan Krios 300 kV electron microscope equipped with a Gatan K2 Summit
direct electron detector. 40 frame movies were collected with a nominal dose of 40 e-/Å2,
a dose rate of ~5 e-/s/phys. pixel and a super resolution pixel size of 0.532Å. The
ZINC9155420-bound TRPV5 data set was collected in a defocus range of 1.0-2.5 µm
under focus. The 10 µM of ZINC17988990-bound TRPV5 data set was collected
between 0.8-1.8 µm under focus.
Data processing
ZINC9155420-bound TRPV5 structure determination
Motioncor2 was used to align each of the 2,278 movies and adjust for beam
induced motion73. CTF estimation was performed using GCTF on the summed movies74.
Subsequent data processing was performed on the dose weighted micrographs in
RELION60,144,145 unless otherwise specified. 1,838 particles were manually picked and
sorted into 2D templates which were used to autopick 510,500 particles from all 2,278
micrographs. Particles were ranked based on Z-score and 474,433 particles with a value
of <0.8 were taken for subsequent rounds of 2D classification to remove false positives
and suboptimal particles. The highest quality 108,354 particles based on the class image
were refined to 5.5 Å using RELION 3D autorefine option without masking. The initial
model was the electron density map of lipid-bound TRPV5 (EMB-7965) filtered to 60Å. A
mask was made of this 5.5Å map by filtering it to 15Å at a threshold of 0.005, extending
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edge by 5 pixels and added a soft edge of 5 pixels. Additional rounds of 2D classification
were performed on the original 474,433 particles and the best 97,702 particles were
selected for 3D refinement using the 5.5Å map as the initial model and masking the
refinement with the mask described above. This produced s 4.9Å map that was
subjected to particle subtraction wherein a cylinder with a radius and height of 35 Å was
isolated from the center of the TMD as described previously128. These subtracted
particles were 3D classified without applying angles and the best 46,384 particles were
unsubtracted and subjected to several rounds of 3D refinement and 3D classification
without applying angles. The final unsharpened map was composed of 21,802 particles
and refined to 4.5Å in RELION. The map was then sharpened using the software bfactor
with an applied b factor of -330 and final resolution was 4.2Å as estimated by
rmeasure113,114. Local resolution was calculating using RESMAP75.
ZINC17988990-bound TRPV5 structure determination
Motioncor2 was used to align each of the 1,340 movies and adjust for beam
induced motion73. CTF estimation was performed using GCTF on the summed movies74.
Subsequent data processing was performed on the dose weighted micrographs in
RELION60,144,145 unless otherwise specified. Laplacian-of-Gaussian reference-free
autopicking was used to pick 30,227 paricles from all 1,340 micrographs. These particles
were then 2D classified to create templates for autopicking. A total of 670,057 particles
were autopicked from all 1,340 micrographs. These particles were subjected to 2D
classification and all particles within the best class with a defocus value >2.0µm as
estimated by GCTF were selected. These 2,639 particles were refined to 15.7Å without
a mask using the electron density map of lipid-bound TRPV5 (EMB-7965) filtered to 60Å
as the initial model. A mask was created of this density map by applying a filter of 15Å at
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a threshold of 0.004 and extending the edge and adding a soft edge of 7 pixels. The
original 670,057 were 2D classified again to rescue more particles and the best 98,516
particles were refined with the mask described above and the filtered lipid-bound TRPV5
as the initial model. These particles were subjected to three rounds of CTF refinement,
bayesian particle polishing and 3D refinement. The final unsharpened refinement was
resolved to 4.06Å and was sharped using the autosharpening feature in PHENIX144 to
3.78Å. Local resolution was calculating using RESMAP75.
Model building and refinement
The previously published lipid-bound TRPV5 structure (PDB: 6DMR) was used
as the initial model for the ZINC17988990-bound TRPV5 structure which was
subsequently used as the initial model for the lower resolution ZINC9155420-bound
TRPV5 structure. Each model was manually adjusted to fit their respective electron
density maps in COOT77 and refined using phenix_realspace_refine115 with imposed
four-fold NCS. Compound restraint files for both compounds were created in PHENIX
using the eLBOW146 AM1 QM method of determining ligand geometry with the SMILES
as the input. The SMILES can be found on the ZINC15 compound database
(http://zinc15.docking.org/). Each compound was docked into the density map using
COOT and the structure underwent several rounds of manual adjustment in COOT
followed by refinement in PHENIX.
For model validation each model was randomized by 0.5Å and refined against its
respective halfmap1. FSC curves of the randomized models vs each of its halfmaps and
the final models vs their respective final map were created using EMAN2. Figures were
made in PYMOL and Chimera118. Pore diagrams were generating using HOLE116.
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Electrophysiology
Whole-cell patch clamp was performed as described earlier27. Briefly, HEK293
cells were cultured in MEM supplemented with 10% FBS in 5% CO2 at 37 °C. Cells were
transfected using the Effectene reagent (Qiagen), and measurements were performed
48–72 h after transfection. Currents were measured with an Axopatch 200B amplifier
using a ramp protocol from –100 mV to 100 mV applied every second. The extracellular
solution contained 142 mM LiCl, 1 mM MgCl2, 10 mM HEPES, and 10 mM glucose, pH
7.4. Monovalent currents were initiated by the same solution containing 1 mM EGTA but
no MgCl2. The intracellular pipette solution contained 140 mM K-gluconate, 10 mM
HEPES, 5 mM EGTA, 2 mM MgCl, and 2 mM ATP, pH 7.3. For both HEK cells and
oocytes, we used a LiCl-based extracellular solution, because in this solution, removal of
extracellular Mg2+ and Ca2+ minimizes the development of endogenous currents in
nontransfected cells, compared to Na+ or K+ based solutions.
Two electrode voltage clamp (TEVC) experiments in Xenopus oocytes were
performed as described earlier27. Briefly, oocytes were digested using 0.2 mg/ml
collagenase (Sigma) in a solution containing 82.5 mM NaCl, 2 mM KCl, 1 mM MgCl2,
and 5 mM HEPES, pH 7.4 (OR2) overnight for ~16 h at 18 °C. Defolliculated oocytes
were kept at 18 °C in OR2 solution supplemented with 1% penicillin/streptomycin
(Mediatech) and 1.8 mM CaCl2. cRNA was microinjected into each oocyte using a
nanoliter injector system (World Precision Instruments). The experiments were
performed 48–72 h after injection. TEVC measurements were performed in a solution
containing 97 mM NaCl, 2 mM KCl, 1 μM MgCl2, and 5 mM HEPES, pH 7.4, monovalent
currents were initiated by a solution containing 96 mM LiCl, 1 mM EGTA, and 5 mM
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HEPES, pH 7.4. Currents were measured with a ramp protocol from -100 to 100 mV
applied every 500 ms, preceded by a step to -100 mV for 50 ms.
All tested compounds were dissolved in DMSO as 10 mM stock solutions. The
stock was further diluted in the experimental buffer. Three compounds did not dissolve at
this concentration in DMSO see Supplemental Table, those compounds were not tested
on TRPV5 inhibition.
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4.6 Figures

Figure 4.1. The effects of novel inhibitors on TRPV5 and TRPV6 activity. HEK293
cells were transfected with rabbit TRPV5 or human TRPV6. Whole cell patch clamp
experiments were performed as described in the methods section (4.5 Methods);
monovalent currents were initiated using a divalent cation free solution. Currents are
shown at 100 and -100 mV; zero currents are indicated by the dashed lines. (A-B)
Representative traces for the effects of ZINC9155420 on (A) TRPV5 and (B) TRPV6
currents, the applications of various concentrations of ZINC9155420 are indicated with
the horizontal lines. (C) Summary of the data, current levels after two minutes of
applying the various concentrations of the compounds were divided by basal current
levels before the application of the drug. The data were fitted using the Hill1 equation
with the Origin 8 software; data are plotted as mean ± SEM (n=6 for each concentration
for TRPV6 and n=8-11 for each concentration for TRPV5). Inset shows the chemical
formula for ZINC9155420. (D-E) Representative traces for the effects of ZINC17988990
on (D) TRPV5 and (E) TRPV6 currents, the applications of various concentrations of
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ZINC17988990 are indicated with the horizontal lines. (F) Summary of the data,
analyzed and plotted as in panel C (n=5-15 for each concentration). Inset shows the
chemical formula for ZINC17988990.
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Figure 4.2. Inhibitor-bound TRPV5 structures. (A) Cryo-EM density map of
ZINC9155420-bound TRPV5 in nanodiscs. A single TRPV5 monomer is colored in teal
while the remaining are shown in grey. Density attributed to bound ZINC9155420 is
shown in pink and lipids are shown in khaki. (B) Atomic model of ZINC9155420-bound
TRPV5 in nanodiscs. ZINC9155420 is shown as pink spheres. (C) Cryo-EM density map
of ZINC17988990-bound TRPV5 in nanodiscs. A single TRPV5 monomer is colored in
red while the remaining are shown in grey. Density attributed to bound ZINC17988990 is
shown in orange and lipids are shown in khaki. Weaker compound density that is not
seen in the halfmaps is shown in light orange. (D) Atomic model of ZINC17988990bound TRPV5 in nanodiscs. ZINC17988990 is shown as orange spheres. The
compound docked in the weaker density is shown in light orange.
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Figure 4.3. ZINC9155420 binding pocket. (A) Cryo-EM density map of the
ZINC9155420 binding pocket. Density attributed to ZINC9155420 is shown in pink.
Lipids are colored in khaki. The TRPV5 protein is depicted with one monomer in teal and
three in grey. (B) (left) Atomic model of the ZINC9155420 binding pocket. (right) Zoomed
in view of the ZINC9155420 binding pocket with residues that could constitute binding
labeled and shown as sticks. The docked ZINC9155420 molecule is shown as pink
sticks and annular lipids are shown in khaki.
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Figure 4.4. ZINC17988990 binding pocket. (A) (left) Atomic model of ZINC17988990
binding pocket. (right) Zoomed in view of the binding pocket with residues that could
constitute binding labeled and shown as sticks. The docked molecule of ZINC17988990
is shown as orange sticks. (B-C) Representative traces for the effects of ZINC17988990
on (B) wild type rbTRPV5 and (C) the Y415F mutant. Whole cell patch clamp
experiments were performed as described in the methods section (4.5 Methods),
monovalent currents were initiated using a divalent cation free solution. Currents are
show at 100 and -100 mV; zero currents are indicated by the dashed lines. (D) Summary
of the data for the wild type rbTRPV5 (replotted from Figure 4.1, dashed line) for the
Y415F and for the D406A mutants, n=3-9 and 5-11 for each concentration for D406 and
Y415F respectively.
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Figure 4.5. Inhibition of TRPV5 by ZINC17988990. (A) Cartoon dimer pore of
ZINC17988990-bound TRPV5 with constriction residues labeled and shown as sticks.
Grey dots indicate the diameter of the pore. (B) Graphical representation of the pore
radii of ZINC17988990-bound (red), lipid-bound (salmon) and PI(4,5)P2-bound TRPV5.
138

The dotted line indicates the radius of a dehydrated calcium ion. Constriction residues
are labeled. (C) Overlay of the lower S1-S4 bundle in ZINC17988990-bound (red) and
lipid-bound (salmon) TRPV5. The arrow indicates the movement caused by
ZINC17988990 binding. (D) Overlay of the lower S1-S4 bundle in ZINC17988990-bound
(red) and PI(4,5)P2-bound (green) TRPV5. The arrows indicate movement necessary for
PI(4,5)P2 activation. (E) Overlay of the inhibitor binding pocket ZINC17988990-bound
(red) and lipid-bound (salmon) TRPV5. The arrows indicate the movement caused by
ZINC17988990 binding. Labels that could constitute ZINC17988990 binding are labeled
and shown as sticks. (F) Overlay of the inhibitor binding pocket ZINC17988990-bound
(red) and PI(4,5)P2-bound (green) TRPV5. The arrows indicate movement necessary for
PI(4,5)P2 activation. Residues that could constitute ZINC17988990 binding are labeled
and shown as sticks.
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Supplementary
Table
Cryo-EM data
collectionand
andvalidation.
model statistics
Table
4.1. Cryo-EM
data1.collection,
refinement

Data collection and processing
Magnification
Voltage (kV)
Defocus range (μm)
Pixel size (Å)
Symmetry imposed
Initial particle images (no.)
Final particle images (no.)
Map resolution (Å)
FSC threshold
Map resolution range (Å)
Refinement
Model resolution cut-off (Å)
FSC threshold
Map sharpening B factor (Å2)
Model composition
Nonhydrogen atoms
Protein residues
Ligands
R.m.s. deviations
Bond lengths (Å)
Bond angles (°)
Validation
MolProbity score
Clashscore
Poor rotamers (%)
Ramachandran plot
Favored (%)
Allowed (%)
Disallowed (%)

ZINC9155420Bound TRPV5
in Nanodiscs

ZINC17988990Bound TRPV5 in
Nanodiscs

~45,500
300
1.0-2.5
1.064
C4
510,500
21,802
4.2
0.143
3.5-5.5

~45,500
300
0.8-2.5
1.064
C4
670,057
98,516
3.78
0.143
3.0-5.0

4.3
0.143
-330

3.78
0.143
-253

0
2392
4

0
2416
4

0.005
0.897

0.006
0.935

1.70
5.02
0.22

1.72
3.88
1.18

93.20
6.80
0.00

91.83
8.17
0.00
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Supplementary Figure 4.1. In silico screening of TRPV5 econazole binding pocket.
Pocket of lipid-bound TRPV5 (PDB: 6DMR) used for in silico screening.
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Supplementary Figure 4.2 Representative traces for the effects of tested
compounds that had no effect on rbTRPV5 activity. Compounds in (A) were tested at
10 μM, compounds in (B) were tested at 3 μM. Experiments were performed and
displayed as in Figure 4.1.
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Supplemental Figure 4.3. The effect of ZINC17988990 on other TRP channels.
HEK293 cells were transfected with the mouse TRPV1, mouse TRPV3, the rat TRPV4
and the rat TRPM8 clones. Whole cell patch clamp experiments were performed as
described in the methods section (4.5 Methods). (A-D) Representative traces for (A)
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TRPV1, (B) TRPV3, (C) TRPV4 and (D) TRPM8. The applications of the various
channel agonists are shown with the horizontal lines above the current traces, the
application of the different concentrations of ZINC17988990 are indicated by horizontal
lines at the bottom. (E-F) Summary of the data at (E) 100 mV and (F) -100 mV. Current
levels after two minutes of applying the various concentrations of the compounds were
divided by agonist-induced current levels before the application of the drugs. Data show
mean ± SEM, n=3-4 for TRPV1, n=3-6 for TRPV3, n=4-6 for TRPV4 and n=5-7 for
TRPM8.
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Supplementary Figure 4.4. The effect of ZINC17988990 on the human TRPV5. (A)
Representative current trace; the applications of various concentrations of the compound
are indicated with the horizontal lines. (B) Summary of the data, current levels after two
minutes of applying the various concentrations of the compounds were divided by basal
current levels before the application of the drugs. The data were fitted using the Hill1
equation with the Origin 8 software; data are plotted as mean ± SEM (n=4-6 for each
concentration).
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Supplementary Figure Z
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Supplementary Figure 4.5. The effects of ZINC17988990 on rbTRPV5 and hTRPV6
expressed in Xenopus oocytes. TEVC experiments were performed as described in
the methods section (4.5 Methods). (A-B) Shows representative traces for rbTRPV5 and
hTRPV6, respectively. (C) Show data summary. Data were analyzed the same way as
for HEK293 cell experiments.
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Supplementary Figure 4.6. The effects of ZINC05626366 on rbTRPV5. (A-B)
Representative traces for whole cell patch clamp experiments in HEK293 cells
expressing rbTRPV5. (C) Data summary, mean +/- SEM n=3-4. Inset shows the
chemical structure of ZINC05626366.
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Supplementary Figure 4.7. Cryo-EM overview of ZINC9155420-bound TRPV5 in
nanodiscs. (A) (left) Representative 2D micrograph of TRPV5 incubated with 10µM
ZINC9155420 in nanodiscs. (right) 2D classes of ZINC9155420-bound TRPV5 in
nanodiscs. (B) FSC curves and model validation curves of ZINC9155420-bound TRPV5
in nanodiscs. (C) Angular distribution of particles used to reconstruct the 3D structure of
ZINC9155420-bound TRPV5 in nanodiscs. Tall red cylinders indicate a larger number of
particles and short blue cylinders indicate fewer particles. (D) Multiple view of the local
resolution of ZINC9155420-bound TRPV5 in nanodiscs. Regions colored blue have local
resolutions of 3.5 Å, white are 4.5 Å and red are 5.5 Å.
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Supplementary Figure 4.8. Data quality of ZINC9155420-bound TRPV5 in
nanodiscs. Various helices of ZINC9155420-bound TRPV5 shown as atomic models
(teal ribbons) with the corresponding cryo-EM density (grey mesh).
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Supplementary Figure 4.9. Cryo-EM overview of ZINC17988990-bound TRPV5 in
nanodiscs. (A) (left) Representative 2D micrograph of TRPV5 incubated with 10µM
ZINC17988990 in nanodiscs. (right) 2D classes of ZINC17988990-bound TRPV5 in
nanodiscs. (B) FSC curves and model validation curves of ZINC17988990-bound
TRPV5 in nanodiscs. (C) Angular distribution of particles used to reconstruct the 3D
structure of ZINC17988990-bound TRPV5 in nanodiscs. Tall red cylinders indicate a
larger number of particles and short blue cylinders indicate fewer particles. (D) Multiple
view of the local resolution of ZINC17988990-bound TRPV5 in nanodiscs. Regions
colored blue have local resolutions of 3.0 Å, white are 4.0 Å and red are 5.0 Å.
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Supplementary Figure 4.10. Data quality of ZINC17988990-bound TRPV5 in
nanodiscs. Various helices of ZINC17988990-bound TRPV5 shown as atomic models
(red

ribbons)

with

the

corresponding
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cryo-EM

density

(grey

mesh).

Supplementary Figure 4.11. Cryo-EM half maps of S4-S5 binding pocket. (A) The
S4-S5 binding pocket in the sharpened map (left), half map 1 (center) and half map 2 of
ZINC9155420-bound TRPV5. Modeled ZINC9155420 is shown as pink sticks. (B) The
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S4-S5 binding pocket in the sharpened map (left), half map 1 (center) and half map 2 of
lipid-bound TRPV5 (PDB: 6DMR, EMB-7965). (C) The S4-S5 binding pocket in the
sharpened map (left), half map 1 (center) and half map 2 of ZINC17988990-bound
TRPV5. Modeled ZINC17988990 is shown as orange sticks. The density maps are
shown as grey mesh. Lipids are shown as khaki sticks.
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Supplementary Figure 4.12. Sequence alignments for binding pockets. (A)
Sequence alignments for the S4-S5 linker of multiple orthologs of TRPV5 and TRPV6.
(B) Sequence alignments for the S1-S4 bundle for various TRP family channels.
rbTRPV5 is highlighted in green. Residues that constitute the compound binding sites
are highlighted in yellow. Sequence conservation is shown above the alignments and
represented as grey boxes.
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Supplementary Figure 4.13. Predicted vs. observed binding. (A) Predicted binding
site for ZINC9155420 based on the in silico screen. (B-C) Observed binding site on the
S4-S5 linker based on the cryo-EM data for (B) ZINC9155420 shown as pink sticks and
(C) ZINC17988990 shown as orange sticks. Lipids are shown as khaki sticks.
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Supplementary Figure 4.14. Cryo-EM half maps of intracellular S1-S4 bundle
binding pocket. (A) The intracellular S1-S4 bundle binding pocket in the sharpened
map (left), half map 1 (center) and half map 2 of ZINC17988990-bound TRPV5. Modeled
ZINC17988990 is shown as orange sticks. (B) The intracellular S1-S4 bundle binding
pocket in the sharpened map (left), half map 1 (center) and half map 2 of ZINC9155420156

bound TRPV5. (C) The intracellular S1-S4 bundle binding pocket in the sharpened map
(left), half map 1 (center) and half map 2 of lipid-bound TRPV5 (PDB: 6DMR, EMB7965). The density maps are shown as grey mesh.
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Supplementary Figure 4.15. Structural divergence between TRPV5 and TRPV6 at
the S2-S3 linker. (A) Cryo-EM density of ZINC17988990-bound TRPV5 in nanodiscs.
The S2-S3 linker is circled and labeled. (B-C) Cryo-EM density of (B) rat TRPV6 in
nanodiscs (EMB-7123) and (C) human TRPV6 in nanodiscs (EMB-7120). The end of the
resolved cryo-EM density for both the S2 and S3 helices are circled.
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Supplementary Figure 4.16. Compound binding in the intracellular S1-S4 bundle.
The intracellular S1-S4 bundle of (A) ZINC17988990-bound TRPV5 with ZINC17988990
shown in orange, (B) lipid-bound TRPV5 with the lipid shown in khaki (PDB: 6DMR), (C)
2-APB-bound TRPV6 (PDB: 6D7O), (D) icilin-bound TRPM8 (PDB: 6NR3) and (E) WS12-bound TRPM8 (PDB: 6NR2). Ligands in C-E are shown in yellow.
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Supplementary Table 4.1. Compounds with no effect on rbTRPV5. List of all ZINC
compounds tested that had either no effect on rbTRPV5 or did not dissolve at 10 μM in
DMSO. N shows the number of experiments performed. Initially all compounds were
tested at 10 μM. After the identification of the first two active compounds, we decreased
the test concentration to 3 μM to identify compounds that are as good or better than the
initial hit compounds.

Number

ZINC ID
ZINC04842851

Supplier Name

Other name(s)

N

CONC.

1

9013994

ZINC04842852

2

10 µM

2

ZINC15814148

15814148

2

10 µM

3

ZINC44755475

44755475

2

10 µM

4

ZINC85145089

85145089

2

10 µM

5

ZINC9292948

9292948

1

10 µM

6

ZINC87111996

87111996

1

10 µM

7

ZINC52372072

52372072

1

10 µM

8

ZINC90584786

90584786

1

10 µM

9

ZINC23914276

23914276

5

10 µM

10

ZINC77564673

99126151

4

10 µM

11

ZINC11578838

11578838

3

10 µM

12

ZINC40566535

Z2788125536

2

10 µM

13

ZINC09258028

Z98621097

2

10 µM

14

ZINC19078588

Z194641002

2

10 µM

15

ZINC34850683

Z55683308

ZINC09510166

2

10 µM

16

ZINC48287288

Z649767680

ZINC48287289

1

10 µM

17

ZINC29099048

Z247091064

1

10 µM

18

ZINC65589127

Z1025060926

1

10 µM

19

ZINC95428543

Z1462246783

1

10 µM

20

ZINC189545218

Z1827853792

1

10 µM

21

ZINC09389941

Z16384331

ZINC09389950

2

10 µM

22

ZINC25054165

Z54077885

Z2241095544, ZINC25054160

2

10 µM

23

ZINC09960474

Z17929723

ZINC09960477

1

10 µM

24

ZINC13148573

Z19243509

ZINC13148574

2

10 µM

25

ZINC09805444

STK117187

ZINC12629272

1

3 µM

26

ZINC02066182

STK367014

1

3 µM

27

ZINC03143326

STK391486

28

ZINC79490144

STL251870

29

ZINC09344575

STK622718

30

ZINC09344575

STL442838

31

ZINC02293820

STL328685

32

ZINC04123131

STK214839

ZINC04123130

3

3 µM

33

ZINC36208021

P-449020260

V016-9987

1

3 µM

34

ZINC31168767

P-25955952

NP-014292, ZINC31168771

1

3 µM

35

ZINC16322278

P-31192293

LT00723737, ZINC16322280

1

3 µM

36

ZINC05067315

P-489249055

EB12699

2

3 µM

37

ZINC40138963

P-18442044

PB447083392, ZINC40138964

1

3 µM

38

ZINC23326129

P-448999809

V014-6317

1

3 µM

39

ZINC08764705

P-13771225

PHAR199755, ZINC25108018

3

3 µM

40

ZINC257316788

LAS52113366

3

3 µM

41

ZINC19340728

IPE21920949

5

3 µM

42

ZINC585290561

LAS57278862

8

3 µM

43

ZINC257283810

LAS51202068

2

3 µM

44

ZINC257264474

BDF33196781

3

3 µM

45

ZINC281297333

Z1982367982

1

3 µM

ZINC09258030

did not dissolve
1
ZINC09344578

3 µM
did not dissolve

3

3 µM
did not dissolve

ZINC19340733
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CHAPTER 5: SUMMARY, IMPACT AND FUTURE DIRECTIONS
5.1 Summary
Here I have presented the summation of my work performed during my graduate
studies. In total six TRPV5 structures are reported in a variety of states which has
created a clear picture of how TRPV5 is activated and inhibited by many types of
modulators. In Chapter 2 we solved the first structure of full length TRPV5. This structure
showed us the overall TRPV5 channel architecture with a similar domain swapped
transmembrane helix orientation to those seen in the rest of the TRPV subfamily.
Interestingly, this structure confirmed that TRPV5 and TRPV6 have very similarly packed
ARDs likely due to the inter-subunit contacts made by the N-terminal helix found on both
of these channels. This is largely divergent structures from the ARD packing of the other
subfamily channels (TRPV1-4). An interesting architectural difference between TRPV5
and TRPV6 was the S2-S3 loop that was resolved in TRPV5 and other TRPV subfamily
channels like TRPV1-2, but not in TRPV6. This has remained consistent throughout the
many structures reported for both TRPV5 and TRPV6. A potential functional relevance
of this divergence was investigated further in Chapter 4. Another key topic of Chapter 2
was the small molecule binding site uncovered in this TRPV5 structure. The non-protein
density was attributed to bound econazole due to the size and shape of the density as
well as the tendency of the binding pocket among TRPV subfamily channels to bind
modulators. Both electrophysiology and molecular dynamics were utilized to confirm that
this pocket was involved in binding.
The structure presented in Chapter 2 is a product of its time and as such its
resolution is limited by the resources that were available when the dataset was collected
in 2016. Optimization of the biological sample by incorporation into nanodisc coupled
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with the utilization of more advanced imaging and data processing techniques that are
available today could very well produce a structure of econazole-bound TRPV5 to higher
resolution. While this structure has given us some essential information regarding the
TRPV5 channel, investigators should always take care in analyzing cryo-EM structures
in the 4.5-5.0Å range. For these structures, the local resolution becomes very important
in that the regions of interest should be in areas of highest resolution, as was the case
for the TMD of TRPV5ECN.
In Chapter 3 we solved the structure of the TRPV5 channel bound to lipids,
PI(4,5)P2 and CaM. The lipid-bound TRPV5 structure revealed the presence of several
lipids bound to the TMD of TRPV5 which could be involved in structural stability of the
channel. The high resolution of this structure also allowed us to clearly place side chains
throughout the structure. This has given us a reference for what is likely TRPV5 in its
resting state. The PI(4,5)P2 structure reported here was the first and only structure of
TRPV5 solved in an ion conducting state so far. The binding site of PI(4,5)P2 was clearly
identifiable in the cryo-EM density map. This binding site had been predicted using
molecular dynamics simulations and was confirmed using electrophysiology. By
comparing the conducting PI(4,5)P2 structure to the lipid-bound TRPV5 structure we
were able to clearly identify residues and helices that underwent rearrangement to
accommodate PI(4,5)P2 binding and trigger channel opening.
Analysis of the CaM-bound TRPV5 structure revealed the binding stoichiometry
and mechanism of CaM induced inhibition of TRPV5. Rather than binding symmetrically
and inducing conformational changes that allosterically regulate ion flow as seen in other
ion channels modulated by CaM, TRPV5 binds a single CaM molecule which sits at the
intracellular gate of TRPV5 and physically obstructs ion permeation. Another interesting
aspect of this structure is that it is the only published TRPV5 structure solved without
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symmetry imposed during reconstruction. Therefore, this structure confirms that TRPV5
is four-fold symmetric in the absence of computer aided symmetry. Overall, the
structures in Chapter 3 give the first insights into the diverse molecular mechanisms of
TRPV5 gating by endogenous modulators.
Chapter 4 investigated novel synthetic modulators of TRPV5 discovered using an
in silico screen based on the structures solved in Chapters 2 and 3. This type of screen
is the first of its kind for the TRP superfamily. While high resolution structures are
becoming more readily available, how we as a field are using them remain limited. By
taking the structural information we had learned from the inhibitor-bound and lipid-bound
TRPV5 structures we were able to identify two compounds that robustly inhibit TRPV5
one of which is specific for TRPV5 over TRPV6 and other TRP family channels.
Interestingly, neither identified inhibitor bound in the location of the original screen. This
could have been due to a variety of reasons from the hydrophobicity of the pocket
allowing for off target hits to the absence of lipids in the in silico screen which could be
important for inhibitor binding. This is the first time a selective modulator for TRPV5 over
TRPV6 has been reported and as such has many potential uses as a scaffold for rational
drug design to target TRPV5 and for analyzing the structure activity relationship (SAR) to
identify which moieties make it specific.
5.2 Impact
The effects of this work on the ever evolving TRP channel field are abundant.
First, the addition of TRPV5 channel structures opens door for molecular dynamics
(MD). One of the limitations of cryo-EM is that is can only give a snapshot of a protein
rather than a dynamic movie. On the other hand, MD is limited by the quality of the
original model. Starting from a high resolution structure is essential for the success of
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MD and the more structures available the better. With these six structures in unique
conformations in a wide range of resolutions (3.8Å-4.8Å) there are now many
opportunities for robust MD analysis of TRPV5. For example, MD is well equipped to
study the structural divergence of TRPV5 and TRPV6 in the S2-S3 loop starting with the
high resolution TRPV5 and TRPV6 structures that are currently available. MD could
uncover the origin of this structural divergence and what effect it may have on the gating
and modulation of the channels.
Another contribution of this work to the TRP channel field is the robust
purification and freezing condition for TRPV5 that we have optimized and reported here.
Both nanodisc and detergent conditions that have the ability to allow for high resolution
structural determination of the channel have been documented and published with these
works. Additionally, the protocol for freezing the channel in vitreous ice appropriate for
cryo-EM data collection has been reported. These methods are valuable because the
two most time intensive steps in cryo-EM structural determination are the optimization of
a protein purification and the optimization of freezing conditions. The high reproducibility
of these methods even with the addition of various ligands have overcome the major
hurtle for producing cryo-EM structures of TRPV5. Moving forward, the utilization of
these methods will allow for the rapid production of directly comparable cryo-EM
structures.
Finally, these studies set an example for the TRP channel field on what can be
done with the cryo-EM structures already available. Specifically, Chapter 4 shows how in
silico screening can be utilized by this field. High resolution TRP channel structures have
been available since the beginning of the Resolution Revolution yet there are no reports
of using in silico screening to uncover novel modulators. The resources such as the
ZINC15 in silico library and Schrödinger small molecule docking software are readily
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available and have been used successfully in other fields that have many structures
solved like the GPCR field131. Now with the majority of mammalian TRP structures
solved, many of which are disease targets, in silico screening of TRP channels could be
the next trend among structural biologists. Even in cases like the one reported in
Chapter 4 where the screened binding pocket and the observed site are different, we still
uncovered valuable modulators of TRPV5 and found new ways of gating the channel.
5.3 Future Directions
Moving forward, there are many biological questions yet to ask about TRPV5 that
can be answered using cryo-EM. For example, another endogenous modulator that was
not investigated here is PKA which has been shown to phosphorylate and activate
TRPV513. At the resolutions now achievable for TRPV5 structural determination by cryoEM, we can reliably investigate post translational modifications such as phosphorylation.
With such a robust understanding of the structure of TRPV5, changes due to
phosphorylation will be more easily identified and the mechanism of action of this
endogenous modulator could be identified. Additionally, while the essential residue
necessary for PKA activation has been determined24, the exact binding site for PKA is
still unknown. A trapped complex of TRPV5 and PKA solved by cryo-EM has the
potential to uncover both the binding site and mechanism of action of PKA induced
TRPV5 activation.
Though here we have investigated several small molecule inhibitors of TRPV5,
there are still several compounds reported that modulate TRPV5 that could be
investigated using cryo-EM. Two cannabinoids, THCV and THCV-OH, are of particular
interest because they are structurally very different from the small molecules
investigated here, yet nearly identical to each other with the only difference being the
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addition of an alcohol group to THCV-OH30. In spite of this small difference between the
molecules, THCV has been reported to be an inhibitor while THCV-OH is thought to be
an activator30. Due to the chemical difference in these molecules compared to the ones
already been investigated coupled with the inverse effect they have on TRPV5 it is
possible that they may interact with TRPV5 at a bind site that has yet to be identified.
Therefore, solving the structure of TRPV5 in the presence of these small molecules
could gain us unique insight into another mechanism of TRPV5 ligand interaction.
Another project with interesting potential for TRPV5 is investigating the reported
human mutations that increase or decrease channel activity16. While we can map the
location of these mutations on to currently available structures, solving the structure of
these mutants will give us definitive answers as to how they alter TRPV5 channel
function. Insights gained from these mutated structures can inspire treatment for the
mutations correlated with recurrent nephrolithiasis. Additionally, studies that focus on the
activated mutant that results in a lower likelihood of contracting calcium stones would be
interesting because calcium absorption is a complicated process. For example, too
much of an increase in TRPV5 activity could lead to problems of calcium toxicity in the
cell. Understanding how human mutations that have a beneficial phenotype overcome
this problem will be very important for developing treatments for nephrolithiasis and
similar calcium homeostasis disorders.
Finally, many studies still must be performed to confirm TRPV5 as a viable target
for the treatment of the calcium homeostasis diseases it is implicated in. One way to
probe the direct contribution of TRPV5 in these diseases is to utilize potent and specific
small molecule modulators. As mentioned above, there are still many ways to optimize
the inhibitors discovered in Chapter 4, but with the open PI(4,5)P2 structure shown in
Chapter 3 there is now the opportunity to screen in an activator binding pocket which
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would likely uncover novel activators of TRPV5. Currently the only exogenous small
molecule that is expected to robustly activate TRPV5 is THCV-OH which has only shown
activity on the zebrafish drTRPV5/TRPV6 orthologue of TRPV5. The drTRPV5/TRPV6
channel has both TRPV5 and TRPV6 properties and it is unlikely that this THCV-OH
compound will have a specific effect on mammalian TRPV5 over TRPV630. Therefore,
there is still untapped potential in searching for specific activators of TRPV5. Utilizing
small molecules in mice models also has the potential to produce acute changes in
calcium homeostasis which could potentially recapitulate those seen in diseases such as
hyperparathyroidism and after a kidney transplant.
5.4 Concluding Remarks
TRPV5 is a highly specialized channel that acts as the fine-tuning regulator of
calcium reabsorption in the kidney. Its critical role in systemic calcium homeostasis is
exemplified by the TRPV5 knockout mice and human mutations of TRPV5 both of which
show changes in calcium excretion and reabsorption. In this work we have presented a
comprehensive foundation regarding the structural basis of TRPV5 gating of select
endogenous and exogenous modulators. These structures in conjunction with the
supported electrophysiology and molecular dynamics experiments have laid the
groundwork for understanding the fine details of modulator binding and conformational
changes associated with TRPV5 gating.
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